AlbionCapital

Albion Crown VCT PLC

Annual Report and Financial Statements
for the year ended 30 June 2024



2024



Albion Crown VCT PLC

(formerly Crown Place VCT PLC)

Annual Report and Financial Statements
for the year ended 30 June 2024

AlbionCapital

COMPANY INFORMATION

Company name	Country of incorporation	Legal form
Albion Crown VCT PLC (the "Company")	United Kingdom	Public Limited Company
Directors	**Company number**	**Auditor**
James Agnew, Chairman Tony Ellingham Pam Garside Ian Spence	03495287	Johnston Carmichael LLP 7-11 Melville Street Edinburgh, EH3 7PE
Manager, company secretary, AIFM and registered office	**Registrar**	**Corporate broker**
Albion Capital Group LLP 1 Benjamin Street London, EC1M 5QL	Computershare Investor Services PLC The Pavilions Bridgwater Road Bristol, BS99 6ZZ	Panmure Liberum Limited Ropemaker Place, Level 12 25 Ropemaker Street London, EC2Y 9LY
Taxation adviser	**Legal adviser**	**Depositary**
Philip Hare & Associates LLP 6 Snow Hill London, EC1A 2AY	Howard Kennedy LLP 1 London Bridge London, SE1 9BG	Ocorian Depositary (UK) Limited Level 5, 20 Fenchurch Street London, EC3M 3BY

The Company is a member of The Association of Investment Companies (www.theaic.co.uk).

Shareholder information

For help relating to dividend payments, shareholdings and share certificates please contact Computershare Investor Services PLC:

Tel: 0370 873 5857 (UK National Rate call, lines are open 8.30am – 5.30pm; Mon – Fri, calls are recorded)

Website: www.investorcentre.co.uk

Shareholders can access holdings and valuation information regarding any of their shares held with Computershare by registering on Computershare's website.

Shareholders can also contact the Chairman directly on: crownchair@albion.capital

Financial adviser information

For enquiries relating to the performance of the Company, and information for financial advisers, please contact the Business Development team at Albion Capital Group LLP:

Email: info@albion.capital

Tel: 020 7601 1850 (lines are open 9.00am – 5.30pm; Mon – Fri; calls are recorded)

Website: www.albion.capital

Please note that these contacts are unable to provide financial or taxation advice.

Contents

Strategic



INVESTMENT POLICY

The Company invests in a broad portfolio of smaller, unquoted growth businesses across a variety of sectors including higher risk technology companies. Investments take the form of equity or a mixture of equity and loans.

Whilst allocation of funds is determined by the investment opportunities which are available, efforts are made to ensure that the portfolio is diversified both in terms of sector and stage of maturity of investee businesses. Funds held pending investment or for liquidity purposes will be held principally as cash on deposit.

Risk diversification and maximum exposures

Risk is spread by investing in a number of different businesses within Venture Capital Trust qualifying industry sectors using a mixture of securities, as permitted. The maximum amount which the Company will invest in a single portfolio company is 15% of the Company's assets at cost thus ensuring a spread of investment risk. The value of an individual investment may increase over time as a result of trading progress and it is possible that it may grow in value to a point where it represents a significantly higher proportion of total assets prior to a realisation opportunity being available.

The Company's maximum exposure in relation to gearing is restricted to the amount of its adjusted share capital and reserves. The Directors do not have any intention of utilising long-term gearing.

FINANCIAL CALENDAR

8 November 2024	Record date for first dividend
Noon on 26 November 2024	Annual General Meeting
29 November 2024	Payment date of first dividend
March 2025	Announcement of Half-yearly results for the six months ending 31 December 2024

FINANCIAL HIGHLIGHTS

0.68p	2.05%	1.61p	32.20p	101.99p
Increase in total shareholder value (pence per share) for the year ended 30 June 2024† (2023: 1.06p)††	Shareholder return for the year ended 30 June 2024 (2023: 3.15%)††	Tax-free dividends per share paid during the year ended 30 June 2024 (2023: 1.63p)	Net asset value per share on 30 June 2024 (2023: 33.13p)	Total shareholder value per share from launch to 30 June 2024† (2023: 101.31p)††

Total shareholder return relative to FTSE All-Share Index total return
(in both cases with dividends reinvested)



Methodology: The total shareholder return, including original amount invested (rebased to 100) from 1 July 2014, assuming that dividends were re-invested at net asset value of the Company at the time that the shares were quoted ex-dividend. Transaction costs are not taken into account.

†Total shareholder value per share at 30 June 2024 is calculated using net asset value per share at 30 June 2024 plus dividends paid per Ordinary share since launch to 30 June 2024.

††These are considered Alternative Performance Measures, see notes 2 and 3 on page 17 of the Strategic report for further explanation.

Albion Crown VCT PLC - Performance Data



The graph above shows the one year, three year, five year and ten year total return to shareholders. This return comprises dividends paid and the change in net asset value over the relevant periods.

Movements in net asset value

		30 June 2024 pence per share		30 June 2023 pence per share
Opening net asset value		**33.13**		33.70
Capital return	***0.48***		0.92	
Revenue return	***0.27***		0.13	
Total return		**0.75**		1.05
Dividends paid		**(1.61)**		(1.63)
Impact from share capital movements		**(0.07)**		0.01
Closing net asset value		**32.20**		33.13

Total shareholder value per share†

Shareholder return from launch to April 2005:	**(pence per share)**
Total dividends paid to 6 April 2005[(i)]	24.93
Decrease in net asset value	(56.60)
Total shareholder return to 6 April 2005	**(31.67)**

Shareholder return from April 2005 to 30 June 2024 (period that Albion Capital has been investment manager):	
Total dividends paid	44.86
Decrease in net asset value	(11.20)
Total shareholder return from April 2005 to 30 June 2024	**33.66**

Shareholder value since launch:	
Total dividends paid to 30 June 2024[(i)]	69.79
Net asset value as at 30 June 2024	32.20
Total shareholder value as at 30 June 2024	**101.99**

Note

(i) Prior to 6 April 1999, Venture Capital Trusts were able to add 20% to dividends and figures for the period up until 6 April 1999 are included at the gross equivalent rate actually paid to shareholders.

A more detailed breakdown of the dividends paid per year can be found at www.albion.capital/vct-funds/CRWN/ under the 'Dividend Payment History' section.

In addition to the dividends paid above, the Board has declared a first dividend for the year ending 30 June 2025 of 0.81 pence per share payable on 29 November 2024 to shareholders on the register on 8 November 2024.

†This is considered an Alternative Performance Measure.

CHAIRMAN'S STATEMENT

James Agnew

Despite the continued challenging macroeconomic backdrop for early stage technology and healthcare companies, I am pleased to report an increase in total shareholder value of 0.68 pence per share for the year ended 30 June 2024, representing a 2.0% uplift on the opening net asset value.

The Board remains encouraged by the progress that is being made by many of the portfolio companies, some of which are highlighted below. The Board recognises the importance of evaluating the Company's returns over the longer-term, as a venture capital portfolio can, by its nature, experience periods of short term volatility.

Results and dividends

As at 30 June 2024, the net asset value ("NAV") was £97.0 million or 32.20 pence per share compared with £94.0 million or 33.13 pence per share at 30 June 2023. This reflects funds raised of £7.5 million during the year and the increase in portfolio value of £2.8 million less dividends paid of £4.5 million. The continuing progress of a number of our portfolio companies is discussed later in this statement and in the Strategic report on page 15.

In line with the dividend policy targeting payment of around 5.0% of NAV per annum, the Company paid ordinary dividends of 1.61 pence per share during the year to 30 June 2024, which equates to 4.9% of the opening NAV (30 June 2023: 1.63 pence per share).

The Board is pleased to declare a first dividend for the year ending 30 June 2025 of 0.81 pence per share, representing 2.5% of the prevailing NAV, to be paid on 29 November 2024 to shareholders on the register on 8 November 2024.

Investment performance and progress

Overall the Company's portfolio has performed well in a continuing difficult environment for early stage technology and healthcare companies and this has contributed to the total uplift in value of £2.8 million to the Company's investments for the year (30 June 2023: £3.8 million). Quantexa, the largest investment within the portfolio (20% of net asset value), was the main contributor to the net gain, increasing its value by £3.9 million, followed by Egress Software Technologies which increased by £1.2 million as detailed below. Other unrealised gains in the year, again driven by strong trading and revenue growth, included Oviva (£1.3 million) and Proveca (£0.8 million). These gains were partially offset by write downs in Chonais River Hydro which decreased by £1.0 million, PeakData by £0.7 million and Solidatus by £0.5 million.

The £1.2 million uplift of our investment in Egress Software Technologies resulted from its sale to KnowBe4, which completed after the period end on 1 July 2024. The Company first invested in Egress in 2014, with follow on investments in 2017 and 2018, and it has delivered a strong return for shareholders of over 7x cost.

The Company realised disposal proceeds of £2.8 million (2023: £0.7 million). During the Company's financial year, we disposed of 7% of our stake in Quantexa, which is now by far our largest investment by value, in conjunction with some of the other Albion VCTs. This was in order to manage our exposure to any individual company. The consideration of £1.2 million received represented a 9.4 times return on the weighted average cost of shares sold, and returned 65% of the cost of our entire holding in Quantexa. The purchasers were experienced financial investors which elected to leave the shares under Albion's management, thus ensuring that Albion's overall influence, including voting rights, would not be diluted. Further details are given in a note to realisations table on page 29. Over the course of the year, Quantexa continued to trade well, and at the year end our holding represented 20.3% of the VCT's net assets. This means that, although the Board remains positive on Quantexa's prospects, the value of our stake still represents an unusually high proportion of our Company's overall value, and thus remains a concentration risk. It is not currently envisaged, however, that there will be an opportunity to reduce our stake further over the shorter term.

Our investment in Ophelos was also sold during the year delivering 2.1 times cost. There were also several investments written off during the year, however their valuations had already been substantially reduced in previous years. Further details on the disposals during the year can be found in the realisations table on page 29.

The three largest investments in the Company's portfolio, Quantexa, Proveca and Oviva are valued at £29.0 million, representing 29.9% of the Company's net asset value.

The Company has been an active investor during the year with £9.4 million invested in 10 new and 14 existing portfolio companies. The new portfolio companies are expected to require further investment as they continue to grow. The following are the five largest new investments:

TREEFERA	OpenDialog	INSTINCT	PAPAYA	Kato
£1.0 million into Treefera, a data management platform providing granular, accurate and trustworthy insights on forests and other nature-based assets	£0.7 million into OpenDialog AI which allows organisations in regulated industries to create and deploy AI powered chatbots and virtual assistants in a no-code environment, to allow for conversational experiences with customers and employees across a variety of communication channels	£0.5 million into Instinct Digital, a platform that enables automated fund and client reporting for asset managers	£0.5 million into Papaya Technologies, a multi-sided platform that connects all the different nodes of the electric vehicle ecosystem (fleet managers, service providers, VaaS, and maintenance)	£0.4 million into GetLeast (T/A Kato), a platform that connects all stakeholders of commercial real estate (landlords, agents, etc.) and allows them to transact more efficiently

A full list of the Company's investments and disposals, including their movements in value for the year, can be found in the Portfolio of investments section on pages 27 to 29.

Board composition

Following a formal selection process, the Board welcomed Tony Ellingham as a non-executive Director on 1 September 2023. When I assumed the Chair following the retirement of Penny Freer, Tony became the Chairman of the Audit and Risk Committee; Pam Garside became the Senior Independent Director; and Ian Spence became the Chairman of the Remuneration Committee.

Risks and uncertainties

The Company faces a number of significant risks, including higher interest rates and the ongoing impact of geopolitical tensions. This complex backdrop is factored into how the Company is managed, including in its management of cash.

Our investment portfolio, while concentrated mainly in the technology and healthcare sectors, remains diversified in terms of both sub-sector and stage of maturity and, importantly, we believe it to be appropriately valued. The Manager is continually assessing the exposure to these risks for each portfolio company and necessary actions, where possible, are being implemented. This includes the potential provision of further financial support to portfolio companies where appropriate.

A detailed analysis of the other risks and uncertainties facing the business is shown in the Strategic report on pages 23 to 26.

Share buy-backs

It remains the Board's primary objective to maintain sufficient resources for investment in existing and new portfolio companies and for the continued payment of dividends to shareholders. The Board's policy is to buy back shares in the market, subject to the overall constraint that such purchases are in the Company's interest. It is the Board's intention for such buy-backs to be in the region of a 5% discount to net asset value, so far as market conditions and liquidity permit. Details of shares bought back during the year can be found in note 15.

Amendment to Investment Management Agreement

On 21 June 2024, the Board announced a variation to the terms of the investment management agreement dated 19 July 2021 between the Company and Albion Capital Group LLP, the Manager, pursuant to which the Manager provides investment management and administrative services to the Company. The variation, following an extensive benchmarking exercise, seeks to align the amounts payable to the Manager for investment management and administration services with current market rates in the Venture Capital Trust industry. Further details on this amendment can be found in the Strategic report on page 18.

Albion VCTs Prospectus Top Up Offers

Your Board, in conjunction with the boards of four other VCTs managed by Albion Capital Group LLP, published a Prospectus Top Up Offer of new Ordinary shares on 15 December 2023. The Offer launched on 2 January 2024 and closed on 8 March 2024 raising the maximum amount of £7.5 million for the Company.

The proceeds raised pursuant to the Offer are added to the liquid resources available for investment, positioning the Company to take advantage of new investment opportunities. Details of the share allotments during the year can be found in note 15.

Merger discussions

On 24 July 2024, the Company announced, as part of a joint announcement with the other Albion managed VCTs, that it had entered into discussions regarding a possible merger with Albion Venture Capital Trust PLC. If the merger proceeds, it is expected to achieve cost savings, administration efficiency and simplicity for shareholders.

Further details are expected to be made available in the Circular and Prospectus due to be published in early November 2024.

The next Shareholder Seminar will be held at 11 Cavendish Square, London, W1G 9EB on 20 November 2024.

Annual General Meeting ("AGM")

The AGM will be held virtually at noon on 26 November 2024 via the Lumi platform. Information on how to participate in the live webcast can be found on the Company's webpage on the Manager's website www.albion.capital/vct-funds/CRWN.

The Board welcomes questions from shareholders at the AGM and shareholders will be able to ask questions using the Lumi platform during the AGM. Alternatively, shareholders can email their questions to crownchair@albion.capital prior to the AGM.

Shareholders' views are important, and the Board encourages shareholders to vote on the resolutions.

Further details on the format and business to be conducted at the AGM can be found in the Directors' report on pages 50 and 51 and in the Notice of the Meeting on pages 92 and 93.

Shareholder seminar

The next Shareholder Seminar will be held at 11 Cavendish Square, London, W1G 9EB on 20 November 2024. The Board and Manager are keen to interact with shareholders and look forward to sharing with you further portfolio updates. Places are limited and to reserve a place please email info@albion.capital with subject heading "Shareholder Seminar" and include your full name. You will receive an email confirmation of your place, subject to availability.

Change of name

On 17 June 2024, it was announced that, following a Board resolution, the Company had changed its name to Albion Crown VCT PLC. This decision was taken in order to closer align the Company with the identity of the other VCTs managed by the investment Manager, Albion Capital Group LLP.

Outlook and prospects

The Board is pleased with the positive results for the year in these uncertain times, with many risks primarily outside the Company's control. The portfolio is well diversified in terms of stage of maturity and target sectors with long term growth characteristics, such as healthcare, software and FinTech, which have minimal dependence on short term consumer expenditure. Therefore, the Board continues to have confidence that the Company is well placed to generate long term value for shareholders. Importantly, the Company continues to provide funding to young and exciting companies with growth ambitions to the benefit of the UK economy, an important objective for VCTs.

James Agnew
Chairman
24 October 2024

STRATEGIC REPORT

The Company is a Venture Capital Trust and its investment policy can be found on page 7.

Business model

As a Venture Capital Trust, the Company has no employees and has outsourced the management of its operations to Albion Capital Group LLP, including secretarial and administrative services. Further details of the Investment Management Agreement can be found on page 18 of this report.

Current portfolio sector allocation

The following pie charts are a useful way of showing the split of the portfolio valuation as at 30 June 2024 by: sector; stage of investment measured by revenues; and size measured by number of employees. Details of the principal investments made by the Company are shown in the Portfolio of investments on pages 27 to 29.

Portfolio analysis by sector

- Cash and net assets 20% (28%)
- FinTech 31% (28%)
- Software & other technology 19% (13%)
- Healthcare (including digital healthcare) 19% (17%)
- Renewable energy 6% (8%)
- Other (including education) 5% (6%)

After adjusting for the sale of Egress on 1 July 2024, the Cash and other net assets sector increases by 2%, and the Software & other technology sector reduces by 2%.

Portfolio analysis by stage of investment

- Early Stage (revenue less than £1 million) 7% (8%)
- Growth (revenue between £1 million and £5 million) 18% (22%)
- Scale up (revenue over £5 million) 75% (70%)

Portfolio analysis by number of employees

- Under 20 6% (5%)
- 21 - 50 18% (13%)
- 51 - 100 15% (19%)
- 101+ 54% (52%)
- Renewable energy* 7% (11%)

*Renewable energy investments have no employees

Comparatives for 30 June 2023 are in brackets

Results and dividends

	£'000
Net capital return for the year ended 30 June 2024	1,379
Net revenue return for the year ended 30 June 2024	786
Total return for the year ended 30 June 2024	**2,165**
First dividend of 0.83 pence per share paid on 30 November 2023	(2,333)
Second dividend of 0.78 pence per share paid on 29 March 2024	(2,190)
Unclaimed dividends	9
Transferred from reserves	**(2,349)**
Net assets as at 30 June 2024	97,044
Net asset value as at 30 June 2024	**32.20 pence per share**

Direction of portfolio

The analysis of the Company's investment portfolio shows that it is well diversified and spread across the FinTech, healthcare (including digital healthcare), software and technology and renewable energy sectors.

Cash has decreased as a proportion of the portfolio to 20% (30 June 2023: 28%). Due to the illiquid nature of the Company's unquoted investments the Board seeks to maintain sufficient cash resources of around 20% of NAV in order for the Company to continue to make new and follow on investments, as well as share buy-backs and dividends. The Company has a significant speciality in FinTech, healthcare and software investing, which account for 69% of the net asset value of the Company.

Results and dividends

The Company paid dividends totalling 1.61 pence per share during the year ended 30 June 2024 (2023: 1.63 pence per share). The dividend objective of the Board is to provide shareholders with a regular dividend flow. The Board has declared a first dividend for the year ending 30 June 2025 of 0.81 pence per share. This dividend will be paid on 29 November 2024 to shareholders on the register on 8 November 2024.

As shown in the Company's Income statement on page 73, the total return for the year was 0.75 pence per share (2023: 1.05 pence per share). The net asset value decreased to 32.20 pence per share (2023: 33.13 pence per share). This decrease in net asset value was primarily due to the payment of 1.61 pence per share of dividends during the year, partly offset by the total return in the year.

Investment income has increased to £1,458,000 (2023: £936,000). This is largely a result of bank deposit interest and income from fixed term funds increasing to £708,000 (2023: £283,000) as a result of rising interest rates. Loan stock income increased to £636,000 (2023: £569,000) which was mainly due to a large interest payment from one of the portfolio companies, Radnor House School (TopCo). Dividend income also increased to £114,000 (2023: £84,000).

The gain on investments for the year was £2,817,000 (2023: gain of £3,846,000). The key drivers of this gain are detailed in the Chairman's statement on pages 10 and 11. A full analysis of the Portfolio of investments can be seen on pages 27 to 29.

The Company saw net outflows of £2,917,000 for the year (2023: outflow of £3,018,000), reflecting new investments, dividends paid, ongoing expenses and the buy-back of shares, offset by disposal proceeds, loan stock income, and the issue of new Ordinary shares under the Top Up Offer.

Review of the business and future changes

A detailed review of the Company's business during the year is contained in the Chairman's statement on pages 10 and 11.

There is a continuing focus on growing the healthcare (including digital healthcare), FinTech and software and other technology sectors. The majority of these investment returns are delivered through equity and capital gains and are expected to be the key driver of success for the Company. Investment income, which is received primarily from our renewable energy investments, is expected to remain steady over the coming years.

Details of significant events which have occurred since the end of the financial year are listed in note 19. Details of transactions with the Manager are shown in note 5.

Future prospects

The Company's financial results for the year ended 30 June 2024 demonstrate that the portfolio remains well balanced across sectors and risk classes, and is largely weathering the ongoing global issues caused as a result of high levels of interest rates and inflation, due in part to the geopolitical tensions, however the full effects of these issues will continue to be felt in years to come. Although there remains much uncertainty, the Board considers that the current portfolio has the potential to deliver long term growth, whilst maintaining a predictable stream of dividend payments to shareholders. Further details on the Company's outlook and prospects can be found in the Chairman's statement on page 13.

Key Performance Indicators ("KPIs") and Alternative Performance Measures ("APMs")

The Directors believe that the following KPIs (some of which are APMs), which are typical for Venture Capital Trusts, used in the Board's assessment of the Company, will provide shareholders with sufficient information to assess how effectively the Company is applying its investment policy to meet its objectives. The Directors are satisfied that the results shown in the following KPIs and APMs give a good indication that the Company is achieving its investment objective and policy.

1. Total shareholder return relative to FTSE All Share Index total return

The graph on page 8 shows the Company's total shareholder return relative to the FTSE All-Share Index total return over the last ten years, with dividends reinvested. The FTSE All-Share Index is considered a reasonable benchmark as the Company is classed as a generalist UK VCT investor, and this index includes over 600 companies listed in the UK, including small-cap, covering a range of sectors. Details on the performance of the net asset value and return per share for the year are shown in the Chairman's statement.

Net asset value per share and cumulative dividends*



* Total shareholder return is net asset value plus cumulative dividends

Methodology: NAV per share is calculated as net assets divided by the number of Ordinary shares in issue (excluding Treasury shares).

2. Net asset value per share and cumulative dividends*

The chart on page 16 illustrates the movement in net asset value per share plus cumulative dividends paid since Albion Capital Group LLP were appointed Manager to 30 June 2024.

3. Shareholder value (APM) and Shareholder return† (APM)

Total shareholder value since inception (being the NAV plus dividends paid) increased by 0.68 pence per share (2.0% on opening NAV) to 101.99 pence per share for the year ended 30 June 2024 as a result of the positive total return of 0.75 pence per share.

The table below shows the total shareholder value has increased 9 out of the last 10 years, with an average annual return of 7.3% per annum.

5. Dividend distributions

Dividends paid in respect of the year ended 30 June 2024 were 1.61 pence per share (2023: 1.63 pence per share) which represents a 4.9% return on opening net asset value. Cumulative dividends paid since launch (on 18 January 1998) amount to 69.79 pence per share.

6. Ongoing charges (APM)

The ongoing charges ratio for the year ended 30 June 2024 was 2.24% (2023: 2.20%). The ongoing charges ratio has been calculated using The Association of Investment Companies' ("AIC") recommended methodology. This figure shows shareholders the total recurring annual running expenses (including investment management fees charged to capital reserve but excluding any performance incentive fees) of £2,076,000 as a percentage of the average net

4. Movement in shareholder value in the year†

2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
4.5%	1.5%	14.0%	14.6%	11.3%	(0.4%)	15.9%	6.1%	3.1%	2.0%

†Methodology: Calculated as the movement in total shareholder value for the year divided by the opening net asset value.

Dividends paid



* Since Albion Capital Group LLP appointed Manager in April 2005

assets attributable to shareholders of £92,480,000. The Directors expect the ongoing charges ratio for the year ahead to increase to approximately 2.63% reflecting the changes in the Management and Administration Fees. Further details on the change in Management and Administration Fees can be found below.

7. VCT compliance*

The investment policy is designed to ensure that the Company continues to qualify and is approved as a VCT by HMRC. In order to maintain its status under Venture Capital Trust legislation, a VCT must comply on a continuing basis with the provisions of Section 274 of the Income Tax Act 2007, details of which are provided in the Directors' report on page 47.

The relevant tests to measure compliance have been carried out and independently reviewed for the year ended 30 June 2024. These showed that the Company has complied with all tests and continues to do so.

Gearing

As defined by the Articles of Association, the Company's maximum exposure in relation to gearing is restricted to the adjusted share capital and reserves. The Directors do not currently have any intention to utilise gearing for the Company.

Operational arrangements

The Company has delegated the investment management of the portfolio to the Manager, Albion Capital Group LLP, which is authorised and regulated by the Financial Conduct Authority. The Manager also provides company secretarial and other accounting and administrative support to the Company.

Investment Management Agreement

Under the Investment Management Agreement ("IMA"), the Manager provides investment management, secretarial and administrative services to the Company. The IMA can be terminated by either party on 12 months' notice and is subject to earlier termination in the event of certain breaches or on the insolvency of either party. During the year the Manager was paid an annual fee equal to 1.75% of the net asset value of the Company, and an annual secretarial and administrative fee of £50,000 per annum. Total annual expenses, including the management fee, are limited to 3% of the net asset value.

Following an extensive benchmarking exercise, the Board announced a variation to the terms of the IMA in order to align the amounts payable to the Manager for investment management and administration services with current market rates in the Venture Capital Trust industry. As a result of the variation, with effect from 1 July 2024, the management fee will be 2.0% of the NAV and the administration fee will be an amount equal to 0.2% of the NAV (capped at £200,000 per annum and with a minimum of £50,000 per annum, with an inflationary review at least every three years). The Board concluded that these changes provide an appropriate level of remuneration and cost coverage for the Manager.

In some instances, the Manager is entitled to an arrangement fee, payable by a portfolio company in which the Company invests, in the region of 2.0% of the investment made, and also monitoring fees where the Manager has a representative on the portfolio company's board.

Management performance incentive fee

In order to align the interests of the Manager and shareholders with regards to generating positive returns, the Manager is entitled to charge an incentive fee in the event that the returns exceed minimum target levels. Under the incentive arrangements, the Company will pay an incentive fee to the Manager of an amount equal to 20% of such excess return that is calculated for each financial year.

The performance hurdle requires that the growth of the aggregate of the net asset value per share and dividends paid by the Company or declared by the Board during the relevant period (both revenue and capital), compared with the previous accounting date, exceeds the average base rate of the Royal Bank of Scotland plc plus 2.0%. If the target return is not achieved in a period, the cumulative shortfall is carried forward to the next accounting period and has to be made up before an incentive fee becomes payable.

For the year ended 30 June 2024, the aggregate of the net asset value per share and dividends paid by the Company or declared by the Board during the relevant

*VCT compliance is not a numerical measure of performance and thus cannot be defined as an APM.

period amounted to 35.44 pence per share, compared to a hurdle of 38.27 pence per share. As a result, no performance incentive fee is payable to the Manager (2023: £nil).

Investment and co-investment

The Company co-invests with other Venture Capital Trusts and funds managed by the Manager. Allocation of investments is on the basis of an allocation agreement which is based, inter alia, on the ratio of funds available for investment.

Evaluation of the Manager

The Board has evaluated the performance of the Manager based on:

- the returns generated by the Company;
- the continuing achievement of the HMRC tests for VCT status;
- the long term prospects of the current portfolio of investments;
- the management of treasury, including use of buy-backs and participation in fund raising; and
- benchmarking the performance of the Manager to other service providers including the performance of other VCTs that the Manager is responsible for managing.

The Board believes that it is in the interests of shareholders as a whole, and of the Company, to continue the appointment of the Manager for the forthcoming year.

Alternative Investment Fund Managers Directive ("AIFMD")

The Board appointed the Manager as the Company's AIFM in 2014 as required by the AIFMD. The Manager is a full-scope Alternative Investment Fund Manager under the AIFMD. Ocorian Depositary (UK) Limited is the appointed Depositary and oversees the custody and cash arrangements and provides other AIFMD duties with respect to the Company.

Consumer duty

The Manager as AIFM is within scope of the FCA's Consumer Duty, but the Company itself is not.

The Manager is a manufacturer of the Company's shares as it is a firm that has some influence over design and distribution of the Company's share product. The Manager's latest assessment of value for the Company's shares was completed in December 2023. The value assessment concluded that the Company provides fair value for shareholders. Where the Manager's product review concludes that changes may help deliver better outcomes for consumers, it will recommend these changes to the Board.

Companies Act 2006 Section 172 Reporting

Under Section 172 of the Companies Act 2006, the Board has a duty to promote the success of the Company for the benefit of its members as a whole in both the long and short term, having regard to the interests of other stakeholders in the Company, such as suppliers, and to do so with an understanding of the impact on the community and environment and with high standards of business conduct, which includes acting fairly between members of the Company.

The Board is very conscious of these wider responsibilities in the ways it promotes the Company's culture and ensures, as part of its regular oversight, that the integrity of the Company's affairs is foremost in the way the activities are managed and promoted. This includes regular engagement with the wider stakeholders of the Company and being alert to issues that might damage the Company's standing in the way that it operates. The Board works closely with the Manager in reviewing how stakeholder issues are handled, ensuring good governance and responsibility in managing the Company's affairs, as well as visibility and openness in how the affairs are conducted.

The Company is an externally managed investment company with no employees, and as such has nothing to report in relation to employee engagement but does keep close attention to how the Board operates as a cohesive and competent unit. The Company also has no customers in the traditional sense and, therefore, there is also nothing to report in relation to relationships with customers.

The table that follows sets out the key stakeholders, details how the Board has engaged with these key stakeholders, and the effect of these considerations on the Company's decisions and strategies during the year.

Engagement with Stakeholder	Decision outcomes based on engagement
Shareholders	
The key methods of engaging with Shareholders are as follows: • Annual General Meeting ("AGM"). • Annual shareholder seminar. • Annual Report and Financial Statements, Half-yearly financial report, and voluntary interim management statements. • RNS announcements in accordance with Listing Rules and Disclosure Guidance and Transparency Rules ("DTRs") covering such things as the publication of a Prospectus. • Albion Capital website, social media pages, as well as publishing Albion News shareholder magazine.	• Shareholders' views are important and the Board encourages Shareholders to exercise their right to vote on the resolutions at the AGM. The Company's AGM is typically used as an opportunity to communicate with investors, including through a presentation made by the Manager. Undertaking this virtually enabled engagement with a wider audience of shareholders from across the country and gave shareholders the opportunity to ask questions and vote during the virtual AGM last year. The virtual medium helps facilitate greater shareholder participation and to help those who are unable to attend the AGM in person, as well as provide a recording of the event for Shareholders to watch on demand. • The next Shareholder Seminar will be held at 11 Cavendish Square, London, W1G 9EB on 20 November 2024. The Board and Manager are keen to interact with shareholders and look forward to sharing with you further portfolio updates. Last year's event took place on 15 November 2023. The seminar included OutThink and Proveca sharing insights into their businesses, Albion executives discussing key factors affecting the investment outlook, as well as a review of the past year and the plans for the year ahead. To reserve your place email info@albion.capital with your full name, subject to availability. • The Board recognises the importance to Shareholders of maintaining a share buy-back policy, in order to provide market liquidity, and considered this when establishing the current policy. The Board closely monitors the discount to the net asset value to ensure this is in the region of 5%. • The Board seeks to create value for Shareholders by generating strong and sustainable returns to provide Shareholders with regular dividends and the prospect of capital growth. The Board takes this into consideration when making the decision to pay dividends to Shareholders. The variable dividend policy has resulted in a dividend yield of 4.9% on opening net asset value. • During the year, the Board made the decision to participate in the Albion Prospectus Top Up Offer, to raise funds for deployment into new and existing portfolio companies. The Prospectus was published on 15 December 2023 and the Offer launched to applications on 2 January 2024. The Board carefully considered whether further funds were required, whether the VCT tests would continue to be met, and whether it would be in the interest of Shareholders, before agreeing to publish the Prospectus. On allotment, an issue price formula based on the prevailing net asset value was used to ensure there was no dilution to existing Shareholders. • Cash management and liquidity of the Company are key quarterly discussions amongst the Board, with focus on deployment of cash for future investments, dividends and share buy-backs. • The Board decided to propose a special resolution at the 2023 AGM to increase the Company's distributable reserves by way of a reduction of the share premium account. This resolution was approved with 98.7% of Shareholders who voted, voting in favour of the resolution. Further details on this can be found on page 50. • Shareholders can contact the Chairman using the email crownchair@albion.capital.



Engagement with Stakeholder	Decision outcomes based on engagement
Manager	
The performance of Albion Capital Group LLP is essential to the long-term success of the Company, including achieving the investment policy and generating returns to shareholders, as well as the impact the Company has on Environment, Social and Governance ("ESG") practice.	• The Manager meets with the Board at least quarterly to discuss the performance of the Company, and is in regular contact in between these meetings, e.g. to share investment papers for new and follow on investments. All strategic decisions are discussed in detail and minuted, with an open dialogue between the Board and the Manager. • The performance of the Manager in managing the portfolio and in providing company secretarial, administration and accounting services is reviewed each year, which includes reviewing comparator engagement terms and portfolio performance. Further details on the evaluation of the Manager, and the decision to continue the appointment of the Manager for the forthcoming year, can be found in this report. • Details of the Manager's responsibilities can be found in the Statement of corporate governance on page 55.
Suppliers	
The key suppliers are: • Auditor; • Corporate broker; • Depositary; • Legal adviser; • Registrar; and • VCT taxation adviser.	• The Manager, on behalf of the Company, is in regular contact with key suppliers and the contractual arrangements with all the principal suppliers to the Company are reviewed regularly and formally once a year, alongside the performance of the suppliers in acquitting their responsibilities. • Following the formal and rigorous audit tender process, the Company was pleased to announce the appointment of Johnston Carmichael LLP as the Company's Auditor. • The Manager reviews the performance of the providers annually and is satisfied with their performance.
Portfolio companies	
The portfolio companies are considered key stakeholders, not least because they are principal drivers of value for the Company. Also, as discussed in the ESG report on pages 41 to 44, the portfolio companies' impact on their stakeholders is also important to the Company.	• The Board aims to have a diversified portfolio in terms of sector and stage of investment. Further details of this can be found in the pie charts on page 14. • In most cases, an Albion executive has either a place on the board of a portfolio company or is an observer, in order to help with both business operation decisions, as well as good ESG practices. • The Manager provides access to deep expertise on growth strategy alignment, leadership team hiring, organisational scaling and founder leader development. • The Manager facilitates good dialogue with portfolio companies, and often organises events in order to help portfolio companies benefit from the Albion network.
Community and environment	
The Company, with no employees, has no effect itself on the community and environment. However, as discussed above, the portfolio companies' ESG impact is extremely important to the Board.	• The Board receives reports on ESG factors within its portfolio from the Manager as it is a signatory of the United Nations Principles for Responsible Investment ("UN PRI"). Further details of this are set out in the ESG report. ESG, without its specific definition, has always been at the heart of the responsible investing that the Company engages in and how the Company conducts itself with all of its stakeholders.



Social and community issues, employees and human rights

The Board recognises the requirement under section 414C of the Companies Act 2006 to detail information about social and community issues, employees and human rights; including any policies it has in relation to these matters and effectiveness of these policies. As an externally managed investment company with no employees, the Company has no formal policies in these matters, however, it is at the core of its responsible investment strategy as detailed above.

General Data Protection Regulation

The General Data Protection Regulation ("GDPR") has the objective of unifying data privacy requirements across the European Union. GDPR forms part of the UK law after Brexit, now known as UK GDPR. The Manager continues to take action to ensure that the Manager and the Company are compliant with the regulation.

Further policies

The Company has adopted a number of further policies relating to:

- Environment;
- Global greenhouse gas emissions;
- Anti-bribery;
- Anti-facilitation of tax evasion; and
- Diversity.

These are set out in the Directors' report on page 48.

Risk management

The Board carries out a regular review of the risk environment in which the Company operates, together with changes to the environment and individual risks. The Board also identifies emerging risks which might impact on the Company. In the period the most noticeable risks have been high interest rates and inflation over the last few years, caused in part by current geopolitical tensions, and volatility in world markets. The full impact of these risks are likely to continue to be uncertain for some time.

The Board has carried out a robust assessment of the Company's principal and emerging risks and uncertainties. It seeks to mitigate these risks through regular reviews of performance and monitoring progress and compliance. The Board applies the principles detailed in the Financial Reporting Council's Guidance on Risk Management, Internal Control and Related Financial and Business Reporting, in the mitigation and management of these risks. More information on specific mitigation measures for the principal risks and uncertainties are explained below:



Possible consequence	Risk assessment during the year	Risk management
Principal Risks		
Risk: Investment, performance, technology, and valuation risk		
The risk of investment in poor quality businesses, which could reduce the returns to shareholders and could negatively impact on the Company's current and future valuations. By nature, smaller unquoted businesses, such as those that qualify for Venture Capital Trust purposes, are more volatile in terms of their performance and valuations, than larger, long-established businesses. Technology investment related risks are also likely to be greater in early, rather than later, stage technology investments, including the risks of the technology not becoming generally accepted by the market or the obsolescence of the technology concerned, often due to greater financial resources being available to competing companies. In addition to this, the Company's investment policy creates concentration risk to the technology sector (including FinTech and HealthTech), as well as to the health sector generally.	Continues to remain high due to the economic and geopolitical issues as referred to in the Chairman's statement.	To reduce this risk, the Board places reliance upon the skills and expertise of the Manager and its track record over many years of making successful investments in this segment of the market. In addition, the Manager operates a formal and structured investment appraisal and review process, which includes an Investment Committee, comprising investment professionals from the Manager for all investments, and at least one external investment professional for investments greater than £1 million in aggregate across all the Albion managed VCTs. The Manager also invites and takes account of comments from non-executive Directors of the Company on matters discussed at the Investment Committee meetings. The Board and Manager regularly review the deployment of investments and cash resources available to the Company in assessing liquidity required for servicing the Company's buy-backs, dividend payments and operational expenses. The decision to issue a Prospectus for the 2023/24 Top-Up followed careful analysis of these factors.
Risk: Valuation risk		
The Company's investment valuation methodology is reliant on the accuracy and completeness of information that is issued by portfolio companies. In particular, the Directors may not be aware of, or take into account, certain events or circumstances which occur after the information issued by such companies is reported. External market conditions, including changes in benchmarks, transaction prices and comparable multiples can also impact the valuations.	No change in the year.	Investments are actively and regularly monitored by the Manager (investment managers normally sit or observe on portfolio company boards), including the level of diversification in the portfolio, and the Board receives detailed reports on each investment as part of the Manager's report at quarterly board meetings. The Board and Manager regularly review the deployment of investments and cash resources available to the Company in assessing liquidity required for servicing the Company's buy-backs, dividend payments and operational expenses. The decision to issue a Prospectus for the 2023/24 Top Up was due to careful analysis of these factors. The unquoted investments held by the Company are designated at fair value through profit or loss and valued in accordance with the International Private Equity and Venture Capital Valuation Guidelines updated in 2022. These guidelines set out recommendations, intended to represent current best practice on the valuation of venture capital investments. The valuation takes into account all known or knowable material facts at the date of valuation.

Possible consequence	Risk assessment during the year	Risk management
Risk: VCT approval risk		
The Company must comply with section 274 of the Income Tax Act 2007 which enables its investors to take advantage of tax relief on their investment and on future returns. Breach of any of the rules enabling the Company to hold VCT status could result in the loss of that status.	No change in the year.	To reduce this risk, the Board has appointed the Manager, which has a team with significant experience in Venture Capital Trust management, used to operating within the requirements of the Venture Capital Trust legislation. In addition, to provide further formal reassurance, the Board has appointed Philip Hare & Associates LLP as its taxation adviser, who report quarterly to the Board to independently confirm compliance with the Venture Capital Trust legislation, to highlight areas of risk and to inform on changes in legislation. Each investment in a new portfolio company is also pre-cleared with our professional advisers or H.M. Revenue & Customs. The Company monitors closely the extent of qualifying holdings and addresses this as required.
Risk: Regulatory and compliance risk		
The Company is listed on The London Stock Exchange and is required to comply with the rules of the Financial Conduct Authority, as well as with the Companies Act, Accounting Standards and other legislation. Failure to comply with these regulations could result in a delisting of the Company's shares, or other penalties under the Companies Act or from financial reporting oversight bodies.	Reduced in the year due to the extension of the Sunset Clause.	As a Venture Capital Trust whose shares are traded on the London Stock Exchange, the Company is impacted by actual and prospective changes to legislation and HMRC guidance governing VCTs. Legislation to extend the VCT scheme until 2035 is now in force. Board members and the Manager have experience of operating at senior levels within or advising quoted companies. Furthermore, the Manager is actively involved with key industry bodies who meet periodically with HMRC and relevant government representatives to ensure that they have a good understanding of relevant sector developments. The Board and the Manager also receive regular updates on new regulation from its auditor, legal advisers and other professional bodies. The Manager's services include ensuring that the Company complies with the relevant rules. The Manager is regulated by the Financial Conduct Authority and has a dedicated compliance function to ensure it complies with rules applicable to its regulated fund management services. Any issues arising from compliance or regulation are reported to the Manager's Executive Committee and, where they relate to the Company, are reported to the Board in quarterly Board meetings.
Risk: Operational and internal control risk		
The Company relies on a number of third parties, in particular the Manager, for the provision of investment management and administrative functions. Failures in key systems and controls within the Manager's business could put assets of the Company at risk or result in reduced or inaccurate information being passed to the Board or to shareholders.	No change in the year.	The Company and its operations are subject to a series of internal controls and review procedures exercised throughout the year. The Board receives reports from the Manager on its internal controls and risk management. The Audit and Risk Committee reviews the Internal Audit Reports prepared by the Manager's internal auditors, Azets and has access to their internal audit partner to whom it can ask specific detailed questions in order to satisfy itself that the Manager has robust systems and controls in place including those in relation to business continuity and cyber security, as mentioned below. Ocorian Depositary (UK) Limited is the Company's Depositary, appointed to oversee the custody and cash arrangements and provide other AIFMD duties. The Board reviews the quarterly reports prepared by Ocorian Depositary (UK) Limited to ensure that the Manager is adhering to its policies and procedures as required by the AIFMD. In addition, the Board annually reviews the performance of its key service providers, particularly the Manager, to ensure they continue to have the necessary expertise and resources to deliver the Company's investment objective and policy. The Manager and other service providers have also demonstrated to the Board that there is no undue reliance placed upon any one individual.

Possible consequence	Risk assessment during the year	Risk management
Risk: Cyber and data security risk		
A cyber-attack on one of the Company's third party suppliers could result in the security of, potentially sensitive, data being compromised, leading to financial loss, disruption or damage to the reputation of the Company.	No change in the year.	The Manager outsources some of its IT services, including hardware and software procurement, server management, backup provision and day-to-day support through an outsourcing arrangement with an IT consultant. In house IT support is also provided. The Manager takes cyber risks seriously and the need to guard against these are in the Service level agreement with our key outsourced service provider. During the year, further investment was made in the Manager's IT infrastructure and awareness training. In addition, the Manager also has a business continuity plan which includes off-site storage of records and remote access provisions. This is revised and tested annually and is also subject to Compliance, Group Risk and Internal Audit reporting. Penetration tests are also carried out to ensure that IT systems are not susceptible to cyber-attacks. The Manager's Internal Auditor performs reviews on IT general controls and data confidentiality and makes recommendations where necessary. The 2023 internal audit focused specifically on IT systems.
Risk: Economic, political and social risk		
Changes in economic conditions, including, for example, interest rates, rates of inflation, industry conditions, competition, political and diplomatic events, and other factors could substantially and adversely affect the Company's prospects in a number of ways. This also includes risks of social upheaval, including from infection and population re-distribution, as well as economic risk challenges as a result of healthcare pandemics/ infection.	Increased in the year, due to the continued high levels of inflation and interest rates and new areas of geopolitical tensions.	The Company invests in a diversified portfolio of companies across a number of industry sectors and in addition often invests in a mixture of instruments in portfolio companies and has a policy of minimising any external bank borrowings within portfolio companies. At any given time, the Company has sufficient cash resources to meet its operating requirements, including share buy-backs and follow on investments. In common with most commercial operations, exogenous risks over which the Company has no control are always a risk and the Company does what it can to address these risks where possible, not least as the nature of the investments the Company makes are long term. The Board and Manager are continuously assessing the resilience of the portfolio, the Company and its operations and the robustness of the Company's external agents, as well as considering longer term impacts on how the Company might be positioned in how it invests and operates. Ensuring liquidity in the portfolio to cope with exigent and unexpected pressures on the finances of the portfolio and the Company is an important part of the risk mitigation in these uncertain times. The portfolio is structured as an all-weather portfolio with c.66 companies which are diversified as discussed above. Exposure is relatively small to at-risk sectors that include leisure, hospitality, retail and travel.
Risk: Liquidity risk		
The Company may not have sufficient cash available to meet its financial obligations. The Company's portfolio is primarily in smaller unquoted companies, which are inherently illiquid as there is no readily available market, and thus it may be difficult to realise their fair value at short notice.	No change in the year.	To reduce this risk, the Board reviews the Company's three year cash flow forecasts on a quarterly basis. These include potential investment realisations, Top Up Offers, dividend payments and operational expenditure. This ensures that there are sufficient cash resources available for the Company's commitments and liabilities as they fall due.

Possible consequence	Risk assessment during the year	Risk management
Emerging Risks		
Risk: Environmental, social and governance ("ESG") risk		
An insufficient ESG policy could lead to an increased negative impact on the environment, including the Company's carbon footprint. Non-compliance with reporting requirements could lead to a fall in demand from investors, reputational damage and penalties. Climate risks could also negatively impact on the value of portfolio investments.	No change in the year.	The Manager is a signatory of the UN PRI and the Board is kept appraised of the evolving ESG policies at quarterly Board meetings. Full details of the specific procedures and risk mitigation can be found in the ESG report on pages 41 to 44. These procedures ensure that this risk continues to be mitigated where possible. Whilst the Company itself has limited impact on climate change, due to no employees nor greenhouse gas emissions, the Board works closely with the Manager to ensure the Manager itself is working towards reducing their impact on the environment, and that the Manager takes account of ESG factors, including the impact on the environment, when making new investment decisions. With specific respect to the Company, a key operation is increasing the use of electronic communications with Shareholders.

Viability statement

In accordance with the FRC UK Corporate Governance Code published in 2018 and provision 36 of the AIC Code of Corporate Governance, the Directors have assessed the prospects of the Company over three years to 30 June 2027. The Directors believe that three years is a reasonable period in which they can assess the ability of the Company to continue to operate and meet its liabilities as they fall due. This is the period used by the Board as part of its strategic planning process, which includes: the estimated timelines for finding, assessing and completing investments; the potential impact of any new regulations; and the availability of cash.

The Board has carried out a robust assessment of the principal and emerging risks facing the Company, including those that could threaten its business model, future performance, solvency or liquidity, and focused on the major factors which affect the economic, regulatory and political environment. The Board carefully assessed, and were satisfied with, the risk management processes in place to avoid or reduce the impact of these risks. The Board has carried out robust stress testing of cashflows which included; factoring in higher levels of inflation when budgeting for future expenses, only including proceeds from investment disposals where there is a high probability of completion, whilst also assessing the requirement for any future financial support of portfolio companies.

The Board has additionally considered the ability of the Company to comply with the ongoing conditions to ensure it maintains its VCT qualifying status under its current investment policy. As a result of the Board's quarterly valuation reviews, it has concluded that the portfolio is well balanced and geared towards delivering long term growth and strong returns to shareholders.

The Board has concluded that there is a reasonable expectation that the Company will be able to continue in operation and meet its liabilities as they fall due over the three year period to 30 June 2027. Additional cashflow forecasts will be prepared in relation to any merger proposal. The Board is mindful of the ongoing risks and will continue to ensure that appropriate safeguards are in place, in addition to monitoring the quarterly cashflow forecasts to ensure the Company has sufficient liquidity.

Companies Act 2006

This Strategic report of the Company for the year ended 30 June 2024 has been prepared in accordance with the requirements of section 414A of the Companies Act 2006 (the "Act"). The purpose of this report is to provide Shareholders with sufficient information to enable them to assess the extent to which the Directors have performed their duty to promote the success of the Company in accordance with Section 172 of the Act.

For and on behalf of the Board

James Agnew
Chairman
24 October 2024

PORTFOLIO OF INVESTMENTS

Portfolio company	Activity	% voting rights	% voting rights held by all Albion* managed funds	At 30 June 2024 Cost £'000	At 30 June 2024 Value £'000	At 30 June 2023 Cost £'000	At 30 June 2023 Value £'000	Change in value for the year** £'000
Quantexa	Network analytics platform to detect financial crime	1.5	12.0	**1,776**	**19,699**	1,797	16,936	**3,940**
Proveca	Reformulation of medicines for children	7.3	49.9	**1,643**	**5,524**	1,190	4,296	**779**
Oviva	A technology enabled service business in medical nutritional therapy (MNT)	2.2	13.8	**1,766**	**3,821**	1,766	2,564	**1,257**
Radnor House School (TopCo)	Independent school for children aged 2 -18 years	8.7	48.3	**1,592**	**3,247**	1,592	3,574	**(327)**
Gravitee Topco (T/A Gravitee.io)	API management platform	3.7	24.4	**1,724**	**2,783**	1,140	1,432	**767**
Runa Network (previously WeGift)	A cloud platform and infrastructure that enables corporates to issue digital incentives and payouts	3.2	17.4	**2,152**	**2,740**	1,652	2,131	**109**
The Evewell Group	Operator and developer of women's health centres focusing on fertility	5.3	34.4	**1,240**	**2,625**	1,240	2,472	**154**
Chonais River Hydro	Owner and operator of a 2 MW hydro-power scheme in the Scottish Highlands	14.0	50.0	**1,549**	**2,410**	1,549	3,438	**(1,028)**
Egress Software Technologies	Encrypted email and file transfer service provider	0.8	21.5	**306**	**2,332**	306	1,161	**1,172**
Healios	Provider of an online platform delivering family centric psychological care	5.7	38.2	**1,915**	**1,963**	1,580	1,972	**(344)**
Cantab Research (T/A Speechmatics)	Provider of low footprint automated speech recognition software	1.8	14.4	**1,521**	**1,723**	1,521	1,788	**(65)**
Gharagain River Hydro	Owner and operator of a 1 MW hydro-power scheme in the Scottish Highlands	15.0	50.0	**1,116**	**1,574**	1,116	1,927	**(353)**
Panaseer	Provider of cyber security services	1.9	14.9	**1,147**	**1,481**	510	752	**92**
Elliptic Enterprises	Provider of anti-money laundering services to digital asset institutions	1.0	7.5	**1,255**	**1,263**	1,114	1,114	**8**
Threadneedle Software Holdings (T/A Solidatus)	Provider of data lineage software	2.2	12.5	**1,239**	**1,239**	1,239	1,739	**(500)**
TransFICC	A provider of a connectivity solution, connecting financial institutions with trading venues via a single API	2.5	15.8	**1,066**	**1,238**	1,066	1,275	**(37)**
Peppy Health	Employee digital healthcare platform for underserved health and wellness areas	1.3	8.7	**1,157**	**1,157**	1,157	1,157	**-**
Convertr Media	Digital lead generation software	4.3	26.7	**680**	**1,091**	680	1,306	**(215)**
NuvoAir Holdings	Digital therapeutics and decentralised clinical trials for respiratory conditions	1.9	12.5	**1,088**	**1,082**	707	997	**(297)**
Treefera	Data platform for forestry and nature-based assets	1.9	13.3	**1,030**	**1,030**	-	-	**-**
Accelex Technology	Data extraction and analytics technology for private capital markets	2.3	15.4	**655**	**966**	433	667	**78**
Tem Energy	Energy trading platform	2.3	14.2	**574**	**954**	193	193	**380**
GX Molecular (T/A CS Genetics)	Develop single-cell sequencing solutions	2.8	22.0	**895**	**899**	615	615	**4**
Beddlestead	Developer and operator of a dedicated wedding venue	8.2	49.0	**1,060**	**854**	1,060	970	**(116)**
Imandra	Provider of automated software testing and an enhanced learning experience for artificial neural networks	1.1	8.1	**720**	**852**	155	225	**61**
The Street by Street Solar Programme	Owns and operates photovoltaic systems on domestic properties	4.4	50.0	**461**	**767**	461	801	**(34)**
PerchPeek	Digital relocation platform	2.4	13.5	**755**	**755**	755	755	**-**

				At 30 June 2024		At 30 June 2023		
Portfolio company	Activity	% voting rights	% voting rights held by all Albion* managed funds	Cost £'000	Value £'000	Cost £'000	Value £'000	Change in value for the year** £'000
OpenDialog AI	AI powered chatbots and virtual assistants	2.9	19.6	**742**	**742**	-	-	**-**
Seldon Technologies	Software company that enables enterprises to deploy Machine Learning models in production	3.5	22.7	**1,193**	**742**	1,193	1,193	**(451)**
Locum's Nest	Provides a technology solution for the management of locum doctors for the NHS	4.1	25.6	**482**	**735**	482	440	**295**
InCrowd Sports	Developer of mobile apps for professional sports clubs	2.7	19.6	**458**	**615**	374	627	**(96)**
Toqio FinTech Holdings	Provider of embedded FinTech solutions	1.4	10.4	**1,017**	**556**	1,017	1,017	**(461)**
OutThink	SaaS platform to measure and manage human risk for enterprises	1.8	12.8	**505**	**505**	505	505	**-**
Regenerco Renewable Energy	Generator of renewable energy from roof top solar installations	3.4	50.0	**344**	**503**	344	518	**(15)**
Aridhia Informatics	Healthcare informatics and analysis provider	2.5	23.6	**442**	**487**	442	476	**11**
Instinct Digital	Investment communication platform for the Asset Manager Industry	3.8	31.6	**486**	**486**	-	-	**-**
Papaya Technologies	Multi-sided marketplace for the EV ecosystem	1.7	15.1	**463**	**463**	-	-	**-**
MHS 1	Education	6.9	48.8	**481**	**451**	481	511	**(60)**
GetLeast (T/A Kato)	Platform that digitises workflows of Commercial Real Estate	2.5	17.5	**433**	**433**	-	-	**-**
Diffblue	AI for code testing/writing platform	2.3	16.2	**425**	**425**	425	425	**-**
Gridcog International	Modelling software for Distributed Energy Resources (DERs)	2.6	15.9	**423**	**423**	-	-	**-**
Alto Prodotto Wind	Owns and operates community scale wind energy projects	4.1	50.0	**235**	**389**	260	445	**(18)**
Trumpet Software	A digital sales room software and a collaboration platform for B2B interactions	1.4	12.2	**370**	**370**	-	-	**-**
Phasecraft	Software for Quantum Computers	0.7	4.7	**358**	**358**	-	-	**-**
PetsApp	Veterinary software	1.7	11.9	**354**	**354**	354	354	**-**
uMedeor (T/A uMed)	A middleware technology platform that enables life science organisations to conduct medical research programmes	3.2	21.4	**598**	**325**	228	308	**(349)**
5Mins AI	Bite-sized workplace learning platform	1.6	11.1	**284**	**284**	284	284	**-**
Kohort Software (previously Ramp Software)	Software platform automating revenue and customer forecasting	1.6	11.3	**217**	**217**	217	217	**-**
Koru Kids	Online marketplace connecting parents and nannies	1.6	9.5	**434**	**202**	421	303	**(114)**
Infact Systems (T/A Infact)	Technology for credit assessment	1.4	10.0	**75**	**155**	75	75	**80**
Kennek Solutions	Vertical software for lenders	0.6	3.9	**147**	**147**	-	-	**-**
Mondra Global	Food supply chain emissions modelling	0.1	0.8	**141**	**145**	-	-	**4**
AVESI	Owns and operates photovoltaic systems on domestic properties	3.8	50.0	**123**	**140**	123	149	**(9)**
Mirada Medical	Developer of medical imaging software	2.0	15.0	**511**	**87**	511	87	**-**
Neurofenix	Neurorehabilitation platform	2.9	19.9	**432**	**77**	432	188	**(111)**
Greenenerco	Owns and operates a 500kW wind project	1.9	50.0	**41**	**72**	44	80	**(1)**
PeakData	Provides insights and analytics to pharmaceutical companies about therapeutic areas	1.7	12.7	**685**	**71**	685	725	**(654)**
Arecor Therapeutics PLC***	Development of biopharmaceuticals through the application of a formulation technology platform	0.2	1.2	**67**	**64**	143	260	**(59)**
Symetrica	A designer and manufacturer of radiation detection equipment	0.2	4.8	**57**	**54**	57	54	**-**
Cisiv	Software and services for non-interventional clinical trials	2.4	23.4	**278**	**45**	278	290	**(245)**
Kew Green VCT (Stansted)	Operator of a Holiday Inn Express hotel at Stansted Airport	2.0	50.0	**22**	**44**	22	51	**(7)**

Portfolio company	Activity	% voting rights	% voting rights held by all Albion* managed funds	At 30 June 2024 Cost £'000	At 30 June 2024 Value £'000	At 30 June 2023 Cost £'000	At 30 June 2023 Value £'000	Change in value for the year** £'000
Black Swan Data	Data analysis that supports corporate decision making	2.1	19.9	**1,471**	**6**	1,471	23	**(17)**
Regulatory Genome Development	Provider of machine readable structured regulatory content	0.8	5.4	**128**	**-**	128	172	**(172)**
Other holdings				**416**	**438**	422	459	**(21)**
Total fixed asset investments				**47,420**	**77,679**	38,012	66,493	**3,015**

* Albion Capital Group LLP

** As adjusted for additions and disposals between the two accounting periods

*** Quoted investment

The comparative cost and valuations for 30 June 2023 do not reconcile to the Annual Report and Financial Statements for the year ended 30 June 2023 as the above list does not include brought forward investments that were fully disposed of in the year.

Realisations in the year to 30 June 2024	Cost £'000	Opening carrying value £'000	Disposal proceeds £'000	Total realised gain/(loss) £'000	(Loss)/gain on opening value £'000
Quantexa (part disposal)*	21	1,177	1,176	1,155	(1)
Ophelos	521	956	1,069	548	113
Arecor	76	138	110	34	(28)
Brytlyt	499	381	8	(491)	(373)
uMotif	1,022	1	1	(1,021)	-
Limitless Technology	412	-	-	(412)	-
DySIS Medical	1,038	169	-	(1,038)	(169)
Loan stock repayments, escrow adjustments and other:					
Proveca	216	221	229	13	8
uMed	76	80	80	4	-
Alto Prodotto Wind	25	38	38	13	-
Greenenerco	5	7	7	2	-
Escrow adjustments and other**	4	-	54	50	54
Total fixed asset investment realisations	**3,915**	**3,168**	**2,772**	**(1,143)**	**(396)**

* The disposal of 2,005 series A shares in Quantexa at the end of 2023 at a price of £586.96 per share, was achieved after an extensive marketing exercise and was considered to be the highest price available under the then prevailing market conditions. It was also equal to the VCT's holding value of the shares at 30 June 2023. The purchasers were experienced financial investors, through an investment vehicle managed by Albion, in which Albion Capital Group LLP, its partners and staff have a 1.5% shareholding. Albion manages the vehicle on normal commercial terms for a transaction of this type, namely an annual management fee of 1% on cost for 4 years, and a performance incentive up to 20% of the excess above a 2 times return on investment. In addition, Albion retains the voting rights over the Quantexa shares. Having taken appropriate regulatory advice, the Board concluded that the disposal of Quantexa shares did not constitute a Related Party Transaction, as defined in the Listing Rules, as its purpose was to benefit the VCT by enabling it to manage excessive concentration risk through reducing its exposure to by far its largest investment at a favourable price.

** These comprise fair value movements on deferred consideration on previously disposed investments, de minimis investments, and expenses which are incidental to the purchase or disposal of an investment.

	£'000
Total change in value of investments for the year	**3,015**
Movement in loan stock accrued interest	74
Unrealised gains sub-total	**3,089**
Realised losses in current year	(396)
Unwinding of discount on deferred consideration	124
Total gains on investments as per Income statement	**2,817**

PORTFOLIO COMPANIES



TOP TEN

1

Quantexa has developed an analytics platform which offers entity resolution, network analytics and automated decisioning at massive scale in real time. This capability is used to fight financial crime and reduce fraud. Quantexa now counts many of the world's largest banks, insurers and governments among its clients.

Audited results for the year ended:	31 March 2023	31 March 2022
	£'000	£'000
Turnover	57,858	37,177
LBITDA	(54,418)	(26,228)
Loss before tax	(54,211)	(26,874)
Net assets	35,725	85,147

Investment information	£'000
Income recognised in the year	-
Total cost	1,776
Total valuation	19,699
Voting rights	1.5%
Voting rights for all Albion* managed funds	12.0%
Basis of valuation	Cost and price of recent investment (calibrated and reviewed for impairment)

quantexa

www.quantexa.com

2

Proveca is a specialty pharmaceutical company focused on children's medicines. The company is addressing a significant need in developing drugs that are specifically formulated for children, taking advantage of a supportive regulatory regime and market protection throughout Europe. Its first product for chronic drooling was launched in 2017 and currently has 2 products. It has a pipeline of drugs focused on neurology, immunology and cardiovascular that it expects to reach the market over the next three years.

Filleted audited results for the year ended:	31 July 2023	31 July 2022
	£'000	£'000
Net liabilities	(3,019)	(2,545)

Investment information	£'000
Income recognised in the year	-
Total cost	1,643
Total valuation	5,524
Voting rights	7.3%
Voting rights for all Albion* managed funds	49.9%
Basis of valuation	Revenue multiple

Proveca Medicines for Children

www.proveca.com

3

Oviva is the category leader in Europe for digital, reimbursed dietetic care. The company sells digital and technology-led services solutions for conditions such as diabetes and obesity. It consistently demonstrates best-in-class outcomes helping its clients save costs and improve patient well-being. It is active in the UK, Germany, France and Switzerland.

Audited results for the year ended:	31 December 2023	31 December 2022
	£'000	£'000
Turnover	26,018	14,123
LBITDA	(17,921)	(14,124)
Loss before tax	(20,965)	(25,409)
Net assets	23,648	43,084

Investment information	£'000
Income recognised in the year	-
Total cost	1,766
Total valuation	3,821
Voting rights	2.2%
Voting rights for all Albion* managed funds	13.8%
Basis of valuation	Cost and price of recent investment (calibrated and reviewed for impairment)

www.oviva.com

4

Radnor House School (TopCo) operates a co-educational independent school near Sevenoaks, Kent. The school is growing strongly with over 500 children on the roll and further capacity to expand. Significant further investment has been made into the school's facilities to enable it to deliver a personalised education experience to each student. The curriculum and co-curricular activities are designed to give each child a wide range of academic and other skills in a supportive and nurturing environment.

Audited results for the year ended:	31 August 2023	31 August 2022
	£'000	£'000
Turnover	10,639	9,338
EBITDA	1,835	1,368
Profit/(loss) before tax	276	(123)
Net assets	18,204	12,238

Investment information	£'000
Income recognised in the year	254
Total cost	1,592
Total valuation	3,247
Voting rights	8.7%
Voting rights for all Albion* managed funds	48.3%
Basis of valuation	Earnings multiple (supported by third party valuation

Radnor House
celebrating every individual
www.radnorhouse.org

5

Gravitee.io operates an API management platform that enables enterprises to manage their APIs through their lifecycle (from design to publishing to controlling access and security).

Filleted audited results for the year ended:	31 December 2023	31 December 2022
	£'000	£'000
Net assets	8,469	6,522

Investment information	£'000
Income recognised in the year	-
Total cost	1,724
Total valuation	2,783
Voting rights	3.7%
Voting rights for all Albion* managed funds	24.4%
Basis of valuation	Cost and price of recent investment (calibrated and reviewed for impairment)

www.gravitee.io

6

Runa Network (previously WeGift) provides a cloud platform and an API that enables corporates to purchase digital gift cards and issue digital payouts to employees and customers. This can be done for a variety of use cases such as HR (employee benefits/rewards), marketing (customer acquisition/activation), loyalty and disbursements. It has built unique technology and direct integrations with over a thousand brands and retailers on the supply side.

Audited results for the year ended:	31 December 2023	31 December 2022
	£'000	£'000
Turnover	28,829	33,762
LBITDA	(11,105)	(8,841)
Loss before tax	(11,225)	(9,054)
Net assets	9,486	9,967

Investment information	£'000
Income recognised in the year	-
Total cost	2,152
Total valuation	2,740
Voting rights	3.2%
Voting rights for all Albion* managed funds	17.4%
Basis of valuation	Cost and price of recent investment (calibrated and reviewed for impairment)

Runa

www.runa.io

7

The Evewell Group owns and operates private women's health centres of excellence with one clinic open on Harley Street and another in Hammersmith, both focusing on fertility and IVF treatment but also uniquely covering all aspects of a woman's gynaecological health.

Filleted audited results for the year ended:	31 December 2023	31 December 2022
	£'000	£'000
Net liabilities	(1,679)	(1,478)

Investment information	£'000
Income recognised in the year	187
Total cost	1,240
Total valuation	2,625
Voting rights	5.3%
Voting rights for all Albion* managed funds	34.4%
Basis of valuation	Earnings multiple

THE EVEWELL

www.evewell.com

8

Chonais River Hydro is a 2MW hydropower scheme near Loch Carron in the Scottish Highlands. It is a run-of-river scheme, taking water from a small river via an intake on the mountainside. The scheme is low visual impact with the only visible components being a small intake and a powerhouse, both of which are built using local material. It generates enough electricity to power approximately 2,000 homes. It benefits from inflation-protected renewable subsidies for a period of 20 years. The scheme was commissioned in 2014 and has been generating successfully since.

Filleted audited results for the year ended:	30 September 2023	30 September 2022
	£'000	£'000
Net liabilities	(216)	(182)

Investment information	£'000
Income recognised in the year	72
Total cost	1,549
Total valuation	2,410
Voting rights	14.0%
Voting rights for all Albion* managed funds	50.0%
Basis of valuation	Discounted cash flow (supported by third party valuation)

9

Egress Software Technologies has developed a secure communication platform that uses encryption and machine learning to secure content shared via e-mail and other applications. Egress serves organisations and small enterprise customers in the public sector, legal, healthcare, financial services and defence sectors. Egress was sold after the year end.

Audited results for the year ended:	31 December 2023	31 December 2022
	£'000	£'000
Turnover	33,630	27,127
LBITDA	(5,969)	(9,276)
Loss before tax	(7,322)	(10,177)
Net liabilities	(23,273)	(17,392)

Investment information	£'000
Income recognised in the year	-
Total cost	306
Total valuation	2,332
Voting rights	0.8%
Voting rights for all Albion* managed funds	21.5%
Basis of valuation	Discounted offer price

egress

www.egress.com

10

Healios is an online platform delivering family centric psychological care primarily to children and adolescents. The Company provides assessment, treatment and early intervention for a variety of mental health conditions.

Audited results for the year ended:	31 December 2023	31 December 2022
	£'000	£'000
Turnover	21,624	17,936
LBITDA	(11,794)	(9,256)
Loss before tax	(13,319)	(8,379)
Net assets/(liabilities)	1,041	(4,454)

Investment information	£'000
Income recognised in the year	-
Total cost	1,915
Total valuation	1,963
Voting rights	5.7%
Voting rights for all Albion* managed funds	38.2%
Basis of valuation	Cost and price of recent investment (calibrated and reviewed for impairment)

Healios
Families feeling better

www.healios.org.uk

* Albion Capital Group LLP

Governance

THE BOARD OF DIRECTORS

The Board provides a wide range of relevant experience and skills. Each member of the Board has demonstrated sufficient time capacity to meet the commitments required in preparing for, attending and participating in periodic Board meetings and for all the activities that take place between formal Board meetings as an important part of the process of oversight and constructive challenge from an independent board of an investment company. The Board works closely together and reviews succession and allocation of responsibilities on a regular basis.

The following are the Directors of the Company, all of whom operate in a non-executive capacity:

James Agnew (appointed 1 November 2015 as a non executive director), Chairman (appointed 22 November 2024), has a background in investment banking and private equity fund management. From 1996 to 2005 he worked for Credit Suisse First Boston in New Zealand and London, where he was involved in a wide range of investment banking transactions including mergers and acquisitions and equity and debt fundraising, as well as general corporate finance advice. He is currently a partner at Harwood Private Equity LLP (formerly J O Hambro Capital Management), which he joined in 2005, where his responsibilities include origination, monitoring and execution of private equity investments.

Tony Ellingham (appointed 1 September 2023), has a background in banking and extensive experience at Board level, particularly with public companies. From 2015 to 2022 he worked for Starling Bank Limited and was Chief Financial Officer from July 2016, responsible for the financial management, treasury and reporting of the bank. Prior to Starling, Tony was at Lloyds Banking Group where he was Finance, Risk & Operations Director of Group Corporate Treasury and Divisional Risk Officer for Finance. He has also held Chief Financial Officer roles at EIIB, Gulf International Bank and Schroder Private Banking.

Pam Garside (appointed 1 March 2019), is an experienced healthcare investor, expert in digital health and an advisor to government, NHS and private sector organisations in the UK and US. She is a Fellow of the Judge Business School at the University of Cambridge and a member of the Investment Committee of Cambridge Enterprise, the technology transfer company of the University. She is Chairman of Cambridge Angels, a board member of several other healthcare companies and co-chair of the Cambridge Health Network.

Ian Spence (appointed 1 May 2020), is highly experienced in the technology sector, having researched and advised companies in this industry over 25 years. He began his career as a journalist at the Investors Chronicle before moving into investment banking where, over the next 13 years working for Granville, Robert W Baird, Bridgewell and Altium, he developed a specialisation as a highly-regarded technology analyst. During this time, he was twice voted TechMARK Analyst of the Year. In 2007, he founded Megabuyte, which has grown to be one of the most respected and widely read sources of financial and corporate intelligence in the European technology sector. Ian is Chairman of the company and is also a non-executive director of AIM-listed telematics software provider Quartix PLC.

All Directors are members of the Audit and Risk Committee and **Tony Ellingham** is Chairman.

All Directors are members of the Nomination Committee and **James Agnew** is Chairman.

All Directors are members of the Remuneration Committee and **Ian Spence** is Chairman.

Pam Garside is the Senior Independent Director.



THE MANAGER

Albion Capital Group LLP, is authorised and regulated by the Financial Conduct Authority and is the Manager of Albion Crown VCT PLC. Established in 1996, Albion Capital is an independent management firm providing investors with access to entrepreneurs who build enduring businesses.

The following are specifically responsible for the management and administration of the Venture Capital Trusts managed by Albion Capital Group LLP:

Will Fraser-Allen, BA (Hons), FCA, has been managing partner since 2019 and chairs the investment committee. He is on the Board of the AIC and sits on the Venture Capital Committee of the BVCA. He joined Albion in 2001 and became deputy managing partner in 2009. He qualified as a chartered accountant and has a BA in History from Southampton University.

Patrick Reeve, MA, FCA, was formerly the managing partner of Albion Capital and became chairman in 2019. He is a director of Albion Technology and General VCT, Albion Enterprise VCT and Albion Development VCT. He joined Close Brothers Group PLC in 1989 before establishing Albion Capital (formerly Albion Ventures LLP) in 1996. Patrick qualified as a chartered accountant and has an MA in Modern Languages from Oxford University. He is on Albion's Valuation Committee and its Risk Management Committee.

Dr. Andrew Elder, MA, FRCS, practised as a neurosurgeon before starting his career in investment. He heads up the healthcare investment team and became deputy managing partner in 2019. He joined Albion in 2005 and became a partner in 2009. He has an MA plus Bachelor of Medicine and Surgery from Cambridge University. He is a Fellow of the Royal College of Surgeons (England).

Vikash Hansrani, BA (Hons), FCA, is a partner and oversees the finance and administration of all funds under Albion's management. He is on Albion's Valuation Committee and its Risk Management Committee. He qualified as a chartered accountant with RSM before joining Albion in 2010. He has a BA in Accountancy & Finance from Nottingham Business School.

Valerie Aelbrecht, MSc, MSc, is an investment manager and joined Albion in 2022. She was at Cherry Ventures after being a founder and operator for 8 years in the FoodTech space. She holds an MSc in Applied Economics from the University of Antwerp and an MSc in International Business Management & Entrepreneurship from Kingston University.

Dr. Leigh Brody, PhD, joined as Investment Manager in 2021 and focuses on transformative technologies and therapeutics opportunities emerging from UCL. She has over a decade of experience as a startup founder, gained her PhD in Biochemistry from Imperial College London, and also holds a BSc in Biochemistry from Simmons University.

Adam Chirkowski, MA (Hons), focuses on B2B and ClimateTech investments and became partner in 2024. Prior to joining Albion in 2013, he spent five years working in corporate finance at Rothschild. He holds a first-class degree in Industrial Economics and a Masters in Corporate Strategy and Governance from Nottingham University.

Emil Gigov, BA (Hons), is a partner focusing on B2B SaaS businesses. He joined Albion in 2000 and became a partner in 2009. He graduated from the European Business School, London, with a BA in European Business Administration.

Dr. Molly Gilmartin, BA, is an investment director and joined in 2022 from McKinsey & Company. Before that, she was Chief Commercial Officer of Induction Healthcare Group which completed an IPO on AIM in 2019. Before this she was a founding team member of start-up Pando and an NHS Clinical Entrepreneur as a medical doctor.

David Grimm, MSc, is a partner focusing on DeepTech investments. He joined Albion in 2016 as investment manager and was made partner in 2023. David has spent 10 years investing in early-stage technology-differentiated opportunities, including 4 years at Spark Ventures prior to joining Albion. He holds an MSc in Natural Sciences.

Ed Lascelles, BA (Hons), heads up the technology investment team. He joined in 2004 having started his career advising public companies and became a partner in 2009. He holds a first-class honours degree in Philosophy from UCL.

Paul Lehair, MSc, MA, joined Albion in 2019 and became partner in 2024. Prior to Albion, he spent five years at Citymapper. He also worked at Viagogo and in M&A at Citigroup. He holds a dual Masters' degree in European Political Economy from the LSE and Political Science and Sciences Po Paris.

Catriona McDonald, BA (Hons), specialises in technology investing. She joined Albion in 2018 and became partner in 2024. Prior to Albion, she came from Goldman Sachs where she worked on IPOs, M&A and leveraged buyouts in New York and London. She graduated from Harvard University, majoring in Economics.

Kibriya Rahman, MMath, is an investment manager and joined Albion in 2022. He was previously at Funding Circle and Formula 1. Before this, he worked at OC&C Strategy Consultants. Kibriya graduated from Oxford University with an MMath degree.

Jane Reddin, BA (Hons), heads up the platform team. She joined Albion in 2020 and became partner in 2022. Prior to Albion, she spent six years as Talent Advisor at Balderton Capital and then co-founded The Talent Stack. She graduated from Durham University with a BA in French and German.

Dr. Christoph Ruedig, MBA, is a partner focusing on digital health. He originally practised radiology and was responsible for M&A in healthcare at GE and venture capital with 3i. He joined Albion in 2011 and became a partner in 2014. He holds a degree in medicine from Ludwig-Maximilians University and an MBA from INSEAD.

Nadine Torbey, MSc, BEng, became a partner in 2024 and joined Albion in 2018 from Berytech Fund Management. She holds a BSc in Electrical and Computer Engineering from the American University of Beirut and an MSc in Innovation Management and Entrepreneurship from Brown University.

Robert Whitby-Smith, BA (Hons), FCA, is a partner focusing on software investing. His background was in corporate finance at KPMG, CSFB and ING Barings, after qualifying as a chartered accountant. He joined Albion in 2005 and became a partner in 2009. He graduated from Reading University with a BA in History.

Jay Wilson, MBA, MMath, is a partner focusing on FinTech. He joined in 2019 from Bain & Co, where he had been a consultant since 2016, and became partner in 2023. Prior to this he graduated from the London Business School with an MBA having spent eight years as a broker at ICAP Securities.

Marco Yu, PhD, MRICS, heads up the renewables team and became partner in 2023. Prior to joining Albion in 2007, he qualified as a Chartered Surveyor with Bouygues and advised on large capital projects with EC Harris. He has a degree in economics from University of Cambridge and a PhD in construction economics from UCL.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE ("ESG") REPORT

The Company's Manager, Albion Capital Group LLP ("Albion"), sees sustainable and responsible investment as an integral part of its investment mandate. In turn, the Board is kept appraised of ESG issues in both the portfolio and in how company affairs are conducted as part of regular Board oversight.

The United Nations Principles for Responsible Investment ("UN PRI") is the world's leading proponent of responsible investment, working to understand the investment implications of ESG factors and to support its international network of investor signatories in incorporating these factors into their investment and ownership decisions.

As a signatory of the UN PRI, Albion (and the Board) recognise that applying the following six principles better aligns investors with broader objectives of society:

Principle 1: to incorporate ESG issues into investment analysis and decision-making processes.

Principle 2: to be active owners and incorporate ESG issues into our ownership policies and practices.

Principle 3: to seek appropriate disclosure on ESG issues by the entities in which we invest.

Principle 4: to promote acceptance and implementation of the Principles within the investment industry.

Principle 5: to work together to enhance our effectiveness in implementing the Principles.

Principle 6: to report on our activities and progress towards implementing the Principles.

The Board and Albion have been conscious in making a commitment to responsible investment in Albion's internal and external processes to ensure alignment with our fundamental commitment to pursuing long term financial returns for our clients. Today we provide finance for promising companies across technology, healthcare and renewable energy. Through this, Albion is directly involved in the oversight and governance of these investments, including ensuring standards of reporting and visibility on business practices, all of which are reported to the Board.

One of the most important drivers of performance is the quality of the investment portfolio, which goes beyond the individual valuations and examines the prospects of each portfolio company and their sectors – all of which requires a long-term view.

Given the nature of venture capital investment, Albion is more intimately involved in the affairs of portfolio companies than typical funds invested in listed securities. As such, Albion can influence good governance and behaviour in portfolio companies, many of which are relatively small without the support of a larger company's administration and advisory infrastructure.

The Company adheres to the principles of the AIC Code of Corporate Governance and is also aware of other governance and corporate conduct guidance which it meets as far as practical. This includes the constitution of a diversified and independent Board capable of providing constructive challenge.

ESG considerations are an integrated part of Albion's full investment process, designed to create value for investors and support portfolio companies in developing sustainable long-term strategies for portfolio companies. This is reflected in the transparency of reporting, governance principles adopted by the Company and the portfolio companies.

Albion integrates ESG across all aspects of the investment process:

STAGE 1 Screening

- Check company activity against internal exclusion list
- Gender tags for all new investment opportunities

STAGE 2 Due diligence

- ESG Due Diligence Questionnaire completed pre-investment
- ESG summary added to Investment committee paper and reviewed at Investment committee
- ESG terms included in Shareholders Agreement template

STAGE 3 Stewardship

- Leverage portfolio company board and platform team to implement ESG initiatives
- Annual mapping of company ESG developments via ESG Balance Score Card (BSC) and identify priorities for year ahead
- Provide and track ESG support via Platform team
- 5 ESG hygiene metrics per company

STAGE 4 Follow ons

- Reassess ESG risks and opportunities during each round of funding
- Use new funding round to check for improvements

STAGE 5 Exit

- Support the company in demonstrating to potential investors how ESG risks have been mitigated and opportunities realised
- To the extent possible, ensure that good ESG practices remain in place following exit

* The ESG Balanced Scorecard ("ESG BSC") is an internal tool used to determine a company's sustainability risks and opportunities, and track progress over time.

PRE-INVESTMENT STAGE

An exclusion list is used to rule out investments in unsustainable, socially detrimental areas. ESG due diligence is performed on each potential portfolio company to identify any sustainability risks, which are ranked from low to high and are reported to the relevant investment committee. Where risks are identified, mitigations are assessed and, if necessary, mitigation plans are put in place. If this is not deemed sufficient, the committee would consider the appropriate level and structure of funding to balance the associated risks. If this is not possible, investment committee approval will not be provided, and the investment will not proceed.

Albion's investment deal documents include a sustainability clause that reinforces individual portfolio company's commitment to driving principles of ESG as it scales.

INVESTMENT STAGE

An ESG clause is integrated into the template of the shareholders' agreement for all new investments, which outlines the portfolio company's commitment to combine economic success with ecological and social success.

All new and existing portfolio companies are asked to report against the ESG BSC annually. It contains sustainability factors (such as whether or not the portfolio company has policies or strategies relating to the environment, carbon emissions or achieving net zero) against which a portfolio company is assessed and scored in order to determine the potential sustainability risks and opportunities arising from the investment. The ESG BSC results form part of Albion's internal risk review meetings and any outstanding issues are addressed in collaboration with portfolio companies with key priority improvement areas identified for the year ahead.

EXIT STAGE

Albion aims to ensure that good ESG practices remain in place following exit by, for example, ensuring that the portfolio company creates a self-sustaining ESG management system during our period of ownership, wherever feasible.

The Manager's ESG initiatives

Albion is guided by the following ESG principles:

Build sustainably: Recognising that the most successful businesses are those that prioritise sustainability, we are committed to driving change and constantly evolving our practices.

Invest responsibly: ESG considerations are entrenched in our investment process and internal operations to create lasting value for all stakeholders.

Contribute positively: We're always motivated to do better through involvement with external initiatives devoted to driving new industry standards and societal outcomes.

Below is an overview of Albion's ESG activity during the reporting period:

ENVIRONMENTAL

- A new platform, Greenly, has been deployed to calculate our emissions
- Albion's supplier data is now captured for a more accurate reporting
- Unavoidable emissions for 2022/23 were offset using Biochar
- Ongoing work on a roadmap to transition Albion to net zero

SOCIAL

- Fair HQ results recognise we have diversity in our team
- Two ongoing, high impact social initiatives:

1. Albion's Social Outreach team has a mandate on local educational outreach
2. Radia Accelerator programme returns for second year to support women entrepreneurs

GOVERNANCE

- Improvement in female presence on portfolio companies' boards
- Increased number of companies with higher overall ESG scores
- BVCA 'Excellence in ESG' award
- Improved UN PRI 2023 private equity score of 69

Signatories

As a signatory of UN Principles for Responsible Investment (UN PRI) Albion is committed to the six key principles to incorporate ESG into investment practice.

Albion is a member of VentureESG steering committee, a venture capital-based non-profit initiative to push the industry on ESG best practices. The current group consists of 300 venture funds and 90 limited partners globally, who work to make ESG a standard part of the due diligence, portfolio stewardship and internal fund management.

Albion is a proud signatory of the Investing in Women Code and commits to adopt internal practices that aim to improve female entrepreneurs' access to the tools, resources and finance required to scale their companies.

PRI Principles for Responsible Investment

SUSTAINABLE DEVELOPMENT GOALS

VentureESG

INVESTING IN WOMEN CODE

DIRECTORS' REPORT

The Directors submit their Annual Report and the audited Financial Statements on the affairs of the Company for the year ended 30 June 2024. The Statement of corporate governance on pages 54 to 60 forms a part of the Directors' report.

BUSINESS REVIEW

Principal activity and status

The principal activity of the Company is that of a Venture Capital Trust. It has been approved by H.M. Revenue & Customs ("HMRC") as a Venture Capital Trust in accordance with the Income Tax Act 2007 and in the opinion of the Directors, the Company has conducted its affairs so as to enable it to continue to obtain such approval. In order to maintain its status under Venture Capital Trust legislation, a VCT must comply on a continuing basis with the provisions of Section 274 of the Income Tax Act 2007 and further details of this can be found on page 47 of this Directors' report.

The Company is not a close company for taxation purposes and its shares are listed on the official list of the London Stock Exchange.

Under current tax legislation, shares in the Company provide tax-free capital growth and income distribution, in addition to the income and capital gains tax relief some investors would have obtained when they invested in the share offers.

Capital structure

Details of the issued share capital, together with details of the movements in the Company's issued share capital during the year are shown in note 15.

Ordinary shares represent 100% of the total share capital and voting rights. The Ordinary shares are designed for individuals who are seeking, over the long term, investment exposure to a diversified portfolio of unquoted investments. The investments are spread over a number of sectors, to produce a regular source of income, combined with the prospect of longer term capital growth.

All Ordinary shares (except for treasury shares which have no right to dividend or voting rights) rank *pari passu* for voting rights and each Ordinary share is entitled to one vote. The Directors are not aware of any restrictions on the transfer of shares or on voting rights.

Shareholders are entitled to receive dividends and the return of capital on winding up or other return of capital based on the surpluses attributable to the shares.

Issue and buy-back of Ordinary shares

During the year the Company issued a total of 26,321,332 Ordinary shares (2023: 36,360,869 Ordinary shares), of which 23,948,789 Ordinary shares (2023: 34,166,296 Ordinary shares) were issued under the Albion VCTs Top Up Offers; and 2,372,543 Ordinary shares (2023: 2,194,573 Ordinary shares) were issued under the Dividend Reinvestment Scheme (details of which can be found on www.albion.capital/vct-funds/CRWN under the Dividend Reinvestment Scheme section).

Your Board, in conjunction with the boards of four other VCTs managed by Albion Capital Group LLP, published a prospectus Top Up offer of new Ordinary shares on 15 December 2023. The Offer launched to applications on 2 January 2024 and closed on 8 March 2024 raising £7.5 million for the Company.

The Company operates a policy of buying back shares either for cancellation or for holding in treasury. Details regarding the current buy-back policy can be found in the Chairman's statement on page 12 and details of share buy-backs during the year can be found in note 15.

Substantial interests and shareholder profile

As at 30 June 2024 and at the date of this Report, the Company was not aware of any shareholder who had a beneficial interest exceeding 3% of the voting rights. There have been no disclosures in accordance with Disclosure Guidance and Transparency Rule 5 made to the Company during the year ended 30 June 2024, and to the date of this report.

Results and dividends

Detailed information on the results and dividends for the year ended 30 June 2024 can be found in the Strategic report on page 15.



Future developments of the business

Details on the future developments of the Company can be found in the Chairman's statement on page 13 and Strategic report on page 16.

Going concern

In accordance with the Guidance on Risk Management, Internal Control and Related Financial and Business Reporting issued by the Financial Reporting Council ("FRC") in 2014, and the subsequent updated Going concern, risk and viability guidance issued by the FRC in 2021, the Board has assessed the Company's operation as a going concern. The Company has sufficient cash and liquid resources, its portfolio of investments is well diversified in terms of sector, and the major cash outflows of the Company (namely investments, buy-backs and dividends) are within the Company's control. Cash flow forecasts are discussed quarterly at Board level with regards to going concern. The cash flow forecasts have been updated and stress tested, which included assessing the resilience of portfolio companies, incorporating the requirement for any future financial support, including proceeds from investment disposals only when there is a high probability of completion, and evaluating the impact of high inflation within the Company. A budget has been prepared for the Company for the three year period to 30 June 2027, which shows adequate cash resources. Accordingly, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence over a period of at least twelve months from the date of approval of the Financial Statements. For this reason, the Directors have adopted the going concern basis in preparing the accounts. The Directors do not consider there to be any material uncertainty over going concern.

The Directors do not consider there to be any material uncertainty over going concern should the proposed merger come into effect.

The Company's policies for managing its capital and financial risks are shown in note 17 and include the Board's assessment of areas including liquidity risk, credit risk and price risk. The Company's business activities, together with details of its performance are shown in the Strategic report and this Directors' report.

Post balance sheet events

Details of events that have occurred since 30 June 2024 are shown in note 19.

Principal risks and uncertainties

A summary of the principal risks faced by the Company is set out on pages 23 to 25 of the Strategic report.

VCT regulation

The investment policy is designed to ensure that the Company continues to qualify and is approved as a VCT by HMRC. In order to maintain its status under Venture Capital Trust legislation, a VCT must comply on a continuing basis with the provisions of Section 274 of the Income Tax Act 2007 as follows:

1	The Company's income must be derived wholly or mainly from shares and securities;
2	At least 80% of the HMRC value of its investments must have been represented throughout the year by shares or securities that are classified as 'qualifying holdings';
3	At least 70% by HMRC value of its total qualifying holdings must have been represented throughout the year by holdings of 'eligible shares'. Investments made before 6 April 2018 from funds raised before 6 April 2011 are excluded from this requirement;
4	At least 30% of funds raised in accounting periods beginning on or after 6 April 2018 must be invested in qualifying holdings by the anniversary of the end of the accounting period in which the funds were raised;
5	At the time of investment, or addition to an investment, the Company's holdings in any one company (other than another VCT) must not have exceeded 15% by HMRC value of its investments;
6	The Company must not have retained greater than 15% of its income earned in the year from shares and securities;
7	The Company's shares, throughout the year, must have been listed on a regulated market;
8	An investment in any company must not cause that company to receive more than £5 million in State aid risk finance in the 12 months up to the date of the investment, nor more than £12 million in total (the limits are £10 million and £20 million respectively for a 'knowledge intensive' company);
9	The Company must not invest in a company whose trade is more than seven years old (ten years for a 'knowledge intensive' company) unless the company previously received State aid risk finance in its first seven years, or the company is entering a new market and a turnover test is satisfied;
10	The Company's investment in another company must not be used to acquire another business, or shares in another company; and
11	The Company may only make qualifying investments or certain non-qualifying investments permitted by Section 274 of the Income Tax Act 2007.

These tests drive a spread of investment risk through preventing holdings of more than 15% by HMRC value in any portfolio company. The tests have been carried out and independently reviewed for the year ended 30 June 2024. The Company has complied with all tests and continues to do so.

'Qualifying holdings' include shares or securities (including unsecured loans with a five year or greater maturity period) in companies which have a permanent establishment in the UK and operate a 'qualifying trade' wholly or mainly in the United Kingdom. The investment must bear a sufficient level of risk to meet a risk-to-capital condition. Eligible shares must comprise at least 10% by HMRC value of the total of the shares and securities that the Company holds in any one portfolio company. 'Qualifying trade' excludes, amongst other sectors, dealing in property or shares and securities, insurance, banking and agriculture. Details of the sectors in which the Company is invested can be found in the pie chart on page 14.

A 'knowledge intensive' company is one which is carrying out significant amounts of R&D from which the greater part of its business will be derived, or where those R&D activities are being carried out by staff with certain higher educational attainments.

Portfolio company gross assets must not exceed £15 million immediately prior to the investment and £16 million immediately thereafter.

On 30 June 2024, the HMRC value of qualifying investments (which includes a 12 month disregard for disposals) was 98.96% (2023: 92.14%). The Board continues to monitor this and all the VCT qualification requirements very carefully in order to ensure that all requirements are met and that qualifying investments comfortably exceed the current minimum threshold, which is 80% required for the Company to continue to benefit from VCT tax status. The Board and Manager are confident that the qualifying requirements can continue to be met during the course of the year ahead.

Environment

The management and administration of the Company is undertaken by the Manager. Albion Capital Group LLP recognises the importance of its environmental responsibilities, monitors its impact on the environment, and designs and implements policies to reduce any damage that might be caused by its activities. The Company has taken initiatives designed to reduce its impact on the environment by favouring digital over printing when communicating with its shareholders. Further details can be found in the Environmental, Social and Governance ("ESG") report on pages 41 to 44.

Global greenhouse gas emissions

The Company qualifies as a low energy user with regards to greenhouse gas emissions, producing less than 40,000kWh of energy, and therefore is not required to report emissions from the operations of the Company, nor does it have responsibility for any other emissions producing sources under the Companies Act 2006 (Strategic report and Directors' reports) Regulations 2013, including those within our underlying investment portfolio. Therefore, the Company is outside of the scope of Streamlined Energy Carbon Reporting.

Anti-bribery

The Company has a zero tolerance approach to bribery, and will not tolerate bribery under any circumstances in any transaction the Company is involved in.

The Manager reviews the anti-bribery policies and procedures of all portfolio companies.

Anti-facilitation of tax evasion

The Company has a zero tolerance approach with regards to the facilitation of criminal tax evasion and has a robust risk assessment procedure in place to ensure compliance. The Board reviews this policy and the prevention procedures in place for all associates on a periodic basis.

Diversity

The Board's policy on the recruitment of new Directors is to attract a range of backgrounds, skills and experience and to ensure that appointments are made on the grounds of merit against clear and objective criteria and bear in mind gender and other diversity within the Board.

The Board is required to disclose their compliance in relation to the targets on board diversity set out under paragraph 6.6.6R (9) of the UK Listing Rules (and corresponding AIC guidance). These are as follows:

(i) At least 40% of the individuals on the Board of Directors are women;
(ii) At least one of the senior positions on the Board of Directors is held by a woman; and
(iii) At least one individual on the Board of Directors is from a minority ethnic background.

The Board of Directors self-reported their gender identity and ethnic background, which offered each of the categories noted in the table below, along with the additional option to indicate an 'other category', should they wish to do so.

As at 30 June 2024, the breakdown of the gender identity and ethnic background of the Board is as follows:

	Number of Board members	Percentage of the Board	Senior Board Position
Gender Identity			
Men	3	75%	1
Women	1	25%	1
Not specified/prefer not to say	-	-	-

	Number of Board members	Percentage of the Board
Ethnic Background		
White British or other White (including minority-white groups)	4	100%
Mixed/Multiple Ethnic Groups	-	-
Asian/Asian British	-	-
Black/African/Caribbean/Black British	-	-
Other ethnic group	-	-
Not specified/prefer not to say	-	-

The Board notes that they met one of the three targets, being at least one of the senior positions on the Board of Directors is held by a woman. Due to the small size of the Board, any change in the board membership will have a much greater impact on representation. The Board takes into consideration the above targets on board diversity, including ethnic background, on the recruitment of new members to the Board.

More details on the Directors can be found in the Board of Directors section on pages 36 and 37.

Packaged Retail and Insurance-based Investment Products ("PRIIPs")

Investors should be aware that the PRIIPs Regulation requires the Manager, as PRIIP manufacturer, to prepare a Key Information Document ("KID") in respect of the Company. This KID must be made available by the Manager to retail investors prior to them making any investment decision and is available on the Company's webpage on the Manager's website. The Company is not responsible for the information contained in the KID and investors should note that the procedures for determining the risks, costs and potential returns are prescribed by the law.

Alternative Investment Fund Managers Directive ("AIFMD")

Under the Alternative Investment Fund Manager Regulations 2013 (as amended) the Company is a UK AIF and the Manager is a full scope UK AIFM. Ocorian Depositary (UK) Limited provides depositary services under the AIFMD.

Material changes to information required to be made available to investors of the Company

The AIFMD outlines the required information which has to be made available to investors prior to investing in an AIF and directs that material changes to this information be disclosed in the Annual Report of the AIF. There were no material changes in the year.

Assets of the Company subject to special arrangements arising from their illiquid nature

There are no assets of the Company which are subject to special arrangements arising from their illiquid nature.

Remuneration (unaudited)

The Manager has a remuneration policy which meets the requirements of the AIFMD Remuneration Code and associated Financial Conduct Authority guidance. The remuneration policy together with the remuneration disclosures for the AIFM's most recent reporting period are available on the Company's webpage on the Manager's website.

Employees

The Company has Albion Capital Group LLP as its Investment Manager and hence has no employees.

Directors

The Directors who held office throughout the year, and their interests in the shares of the Company (together with those of their immediate family) are shown in the Directors' remuneration report on page 63.

Directors' indemnity

Each Director has entered into a Deed of Indemnity with the Company which indemnifies each Director, subject to the provisions of the Companies Act 2006 and the limitations set out in each deed, against any liability arising out of any claim made against themselves in relation to the performance of their duties as a Director of the Company. A copy of each Deed of Indemnity entered into by the Company with each Director is available at the registered office of the Company. The Company also has Directors' & Officers' Liability Insurance in place. Further details of this can be found in the Director's remuneration report on page 62.

Re-election of Directors

Directors' re-election is subject to the Articles of Association and the UK Corporate Governance Code. The AIC Code recommends that all Directors submit themselves for re-election annually, therefore in accordance with the AIC Code, James Agnew, Tony Ellingham, Pam Garside and Ian Spence will offer themselves for re-election.

Advising ordinary retail investors

The Company currently conducts its affairs so that its shares can be recommended by financial intermediaries to ordinary retail investors in accordance with the FCA's rules in relation to non-mainstream investment products and intends to continue to do so for the foreseeable future. The FCA's restrictions which apply to non-mainstream investment products do not apply to the Company's shares because they are shares in a Venture Capital Trust which, for the purposes of the rules relating to non-mainstream investment products, are excluded securities and may be promoted to ordinary retail investors without restriction.

Investment and co-investment

The Company co-invests with other Albion Capital Group LLP managed VCTs. Allocation of investments is on the basis of an allocation agreement which is based, inter alia, on the ratio of cash available for investment in each of the entities and the HMRC VCT qualifying tests.

Auditor

The Audit and Risk Committee annually reviews and evaluates the standard and quality of service provided by the Auditor, as well as value for money in the provision of these services.

As announced on 30 October 2023, following a formal and rigorous audit tender process, the Company was pleased to announce the appointment of Johnston Carmichael LLP ("Johnston Carmichael") As the Company's Auditor with immediate effect. Johnston Carmichael have conducted the audit of the Annual Report and Financial Statements for the year ended 30 June 2024.

Cancellation of share premium

The Company obtained authority to cancel the amount standing to the credit of its share premium reserve at the Annual General Meeting on 22 November 2023. The purpose of the proposal was to increase the distributable reserves available to the Company for the payment of dividends, the buy-back of shares, and for other corporate purposes.

The proposal received the consent of the Court on 14 May 2024, and the changes have been registered at Companies House on 29 May 2024. Over time, this will create additional distributable reserves of £54.8 million.

Annual General Meeting

The Company's Annual General Meeting ("AGM") will be held virtually at noon on 26 November 2024 via the Lumi platform. Information on how to participate in the live webcast can be found on the Company's webpage at www.albion.capital/vct-funds/CRWN.

The AGM will include a presentation from the Manager, the answering of questions received from shareholders and the formal business of the AGM, which includes voting on the resolutions proposed by the Board. The Chairman will elect at the meeting that voting on the resolutions will take place by way of a poll. Registration details for the webcast will be emailed to shareholders and will be available at www.albion.capital/vct-funds/CRWN prior to the AGM.

The Board welcomes questions from shareholders at the AGM and shareholders will be able to ask questions using the Lumi platform during the AGM. Alternatively, shareholders can email their questions to crownchair@albion.capital prior to the AGM. Questions asked will be answered during the meeting as far as possible.

Given that the Company has nearly 10,000 shareholders, to enable the Board and the Manager to respond to questions, and to ensure sufficient time is devoted to managing the assets on behalf of the shareholders, we ask that you submit no more than two questions per shareholder, which should be of a substantive nature and relating to the business being dealt with at the meeting.

Shareholders will be able to vote during the AGM using the Lumi platform. Shareholders are encouraged to complete and return proxy cards in advance of the AGM but those participating in the Meeting will be able to cast their votes through the Lumi platform once the Chairman declares the poll open.

The results of the poll held at the AGM will be announced through a Regulatory Information Service and will be published on the Company's webpage on the Manager's website at www.albion.capital/vct-funds/CRWN as soon as reasonably practicable following the Meeting.

Shareholders' views are important, and the Board encourages shareholders to vote on the resolutions. You can cast your vote by using the proxy form enclosed with this Annual Report or electronically at www.investorcentre.co.uk/eproxy. The Board has carefully considered the business to be approved at the AGM and recommends shareholders to vote in favour of all the resolutions being proposed.

Annual General Meeting (continued)

Full details of the business to be conducted at the AGM are given in the Notice of the Meeting on pages 92 and 93.

The ordinary business resolutions 1 to 8 include receiving and adopting the Company's accounts, to approve the Directors' remuneration report, to re-elect Directors, and to re-appoint Johnston Carmichael LLP as auditor for the next year end and to fix their remuneration.

Resolutions relating to the following items of special business will be proposed at the forthcoming AGM for which shareholder approval is required in order to comply either with the Companies Act or the UK Listing Rules of the Financial Conduct Authority.

Resolution numbers 9 to 11 replace the authorities given to the Directors at the AGM in 2023. The authorities sought at the forthcoming AGM will expire 15 months from the date that the resolution is passed or at the conclusion of the next AGM of the Company, whichever is earlier.

Authority to allot shares

Ordinary resolution number 9 will request the authority to allot up to an aggregate nominal amount of £691,031 representing approximately 20% of the issued Ordinary share capital of the Company as at the date of this report.

During the year, Ordinary shares were allotted as described in detail in note 15.

The Directors' current intention is to allot shares under the Dividend Reinvestment Scheme and any Albion VCTs Top Up Offers. The Company currently holds 45,787,992 Ordinary shares in treasury which represents 13.2% of the total Ordinary share capital in issue as at 30 June 2024.

Disapplication of pre-emption rights

Special resolution number 10 will request the authority for the Directors to allot equity securities for cash without first being required to offer such securities to existing members. This will include the sale on a non pre-emptive basis of any shares the Company holds in treasury for cash. The authority relates to a maximum aggregate of £691,031 of the nominal value of the share capital representing approximately 20% of the issued Ordinary share capital of the Company as at the date of this report.

Purchase of own shares

Special resolution number 11 will request the authority to purchase 14.99% of the Company's issued Ordinary share capital at, or between, the minimum and maximum prices specified in resolution 11. Shares bought back under this authority may be cancelled or held in treasury.

The Board believes that it is helpful for the Company to continue to have the flexibility to buy its own shares and this resolution seeks authority from shareholders to do so. During the year under financial review, the Company purchased 2,502,101 Ordinary shares which are held in treasury, at an aggregate consideration of £791,000 representing 0.7% of called up share capital, and 6,030,596 Ordinary shares which were cancelled, at an aggregate consideration of £1,770,000 representing 1.7% of called up share capital.

Notice period for General Meetings

Special resolution number 12 proposes that a General Meeting, other than an Annual General Meeting, may be called on not less than 14 clear days' notice.

The current notice period is 21 days. This change has been proposed in order to provide the Chair of the Board with additional flexibility in scheduling and arranging General Meetings going forward, which we believe is in the best interest of the Company. This can be beneficial in instances such as if the Company wanted to cancel its share premium reserve in order to increase its distributable reserves through a General Meeting or other matters that may require a General Meeting and help facilitate these meetings quicker.

Recommendation

The Board believes that the passing of the resolutions above are in the best interests of the Company and its shareholders as a whole, and unanimously recommends that you vote in favour of these resolutions, as the Directors intend to do in respect of their own shareholdings.

Disclosure of information to the Auditor

In the case of the persons who are Directors of the Company at the date of approval of this report:

- so far as each of the Directors are aware, there is no relevant audit information of which the Company's Auditor is unaware; and
- each of the Directors has taken all the steps that they ought to have taken as a Director to make themselves aware of any relevant audit information and to establish that the Company's Auditor is aware of that information.

This disclosure is given and should be interpreted in accordance with the provisions of Section 418 of the Companies Act 2006.

By Order of the Board

Albion Capital Group LLP
Company Secretary
1 Benjamin Street
London, EC1M 5QL
24 October 2024

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The Directors are responsible for preparing the Annual Report and Financial Statements in accordance with applicable law and regulations.

Company law requires the Directors to prepare Financial Statements for each financial year. Under that law the Directors have elected to prepare the Company's Financial Statements in accordance with United Kingdom Generally Accepted Accounting Practice ("UK GAAP") (United Kingdom Accounting Standards and applicable law). Under company law the Directors must not approve the Financial Statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss for the Company for that period.

In preparing these Financial Statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether they have been prepared in accordance with UK GAAP subject to any material departures disclosed and explained in the Financial Statements;
- prepare the Financial Statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business; and
- prepare a Directors' report, a Strategic report and Directors' remuneration report which comply with the requirements of the Companies Act 2006.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the Financial Statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Website publication

The Directors are responsible for ensuring the Annual Report and Financial Statements are made available on a website. Financial Statements are published on the Company's webpage on the Manager's website (www.albion.capital/vct-funds/CRWN) in accordance with legislation in the United Kingdom governing the preparation and dissemination of Financial Statements, which may vary from legislation in other jurisdictions. The Company's webpage is maintained on the Board's behalf by the Manager.

The work carried out by the Auditor does not involve consideration of the maintenance and integrity of this website and, accordingly, the Auditor accepts no responsibility for any changes that have occurred to the Financial Statements since they were initially presented on the website.

Directors' responsibilities pursuant to Disclosure Guidance and Transparency Rule 4 of the UK Listing Authority

The Directors confirm to the best of their knowledge:

- The Financial Statements have been prepared in accordance with UK GAAP and give a true and fair view of the assets, liabilities, financial position and profit of the Company; and
- The Annual Report includes a fair review of the development and performance of the business and the financial position of the Company, together with a description of the principal risks and uncertainties that it faces; and
- The Annual Report and Financial Statements taken as a whole is fair, balanced and understandable and provides the information necessary for shareholders to assess the Company's position and performance, business model and strategy.

For and on behalf of the Board

James Agnew
Chairman
24 October 2024

STATEMENT OF CORPORATE GOVERNANCE

Background

The Financial Conduct Authority requires all companies listed on a regulated market to disclose how they have applied the principles and complied with the provisions of the UK Corporate Governance Code (the "Code") issued by the Financial Reporting Council ("FRC") in 2018.

The Board has considered the Principles and Provisions of the AIC Code of Corporate Governance ("AIC Code"). The AIC Code addresses the Principles and Provisions set out in the Code, as well as setting out additional Provisions on issues that are of specific relevance to the Company and other investment companies. Closed-ended investment companies have particular factors which have an impact on their governance arrangements, principally from four features: outsourcing their day to day activities to external service providers and being governed by boards of non-executive directors; the importance of the Manager in the outsourcing compared to a typical supplier; having no executive directors or employees and consequently no executive remuneration packages; and no customers in the traditional sense, only shareholders.

The Board considers that reporting against the Principles and Provisions of the AIC Code, which has been endorsed by the FRC, provides more relevant information to shareholders. The Company has complied with the Principles and Provisions of the AIC Code.

The AIC Code is available on the AIC website (www.theaic.co.uk). It includes an explanation of how the AIC Code adapts the Principles and Provisions set out in the Code to make them relevant for investment companies.

Board of Directors

The Board consists solely of independent non-executive Directors. James Agnew is the Chairman, Tony Ellingham is the Chairman of the Audit and Risk Committee, Pam Garside is the Senior Independent Director and Ian Spence is the Chairman of the Remuneration Committee. As all Directors are non-executive, day-to-day management responsibilities are sub-contracted to the Manager. The Board will continue to act independently of the Manager and the Directors consider that the size of the Board is adequate to meet the Company's future needs.

The Board does not have a policy of limiting the tenure of any Director as the Board does not consider that a Director's length of service reduces their ability to act independently of the Manager.

The AIC Code requires that all Directors submit themselves for re-election annually, therefore in accordance with the AIC Code, James Agnew, Tony Ellingham, Pam Garside and Ian Spence will offer themselves for re-election.

The Directors have a range of business and financial skills which are relevant to the Company; these are described in the Board of Directors section on pages 36 and 37. All of the Directors have demonstrated that they have sufficient time, skill and experience to acquit their Board responsibilities and to work together effectively. Directors are provided with key information on the Company's activities, including regulatory and statutory requirements, and internal controls, by the Manager. The Board has access to secretarial advice and compliance services by the Manager, who is responsible for ensuring that Board procedures are followed and applicable procedures complied with. All Directors are able to take independent professional advice in furtherance of their duties if necessary. The Company has in place Directors' & Officers' Liability Insurance.

The Directors consider its membership is diverse in relation to experience and balance of skills. Further details on diversity can be found on pages 48 and 49. Further details on the recruitment of new Directors can be found in the Nomination Committee section on page 58.

The Board met four times during the year as part of its regular programme of Board meetings, with all Directors attending each meeting. The table below sets out the Directors' attendance at Board and Committee meetings during the year ended 30 June 2024, with the number of meetings each Director was eligible to attend in brackets.

	Board	Audit and Risk Committee	Nomination Committee	Remuneration Committee
James Agnew	4 (4)	2 (2)	1 (1)	1 (1)
Tony Ellingham	4 (4)	2 (2)	1 (1)	1 (1)
Pam Garside	4 (4)	2 (2)	1 (1)	1 (1)
Ian Spence	4 (4)	2 (2)	1 (1)	1 (1)

A sub-committee of the Board comprising at least two Directors met during the year to allot shares issued under the Dividend Reinvestment Scheme and the Albion VCTs Top Up Offers and also met during the year to approve the terms and contents of the Offer Documents under the Albion VCTs' Prospectus Top Up Offers, and the appointment of Johnston Carmichael as the Company's Auditor. There is regular contact between individual members of the Board. Representatives of the Manager attend Board meetings and participate in Board discussions, other than on matters where there might be a perceived conflict of interest between the Manager and the Company.

The Chairman ensures that all Directors receive, in a timely manner, all relevant management, regulatory and financial information. The Board receives and considers reports regularly from the Manager and other key advisers, and ad hoc reports and information are supplied to the Board as required. The Board has a formal schedule of matters reserved for it and the agreement between the Company and its Manager sets out the matters over which the Manager has authority and limits beyond which Board approval must be sought.

The Manager has authority over the management of the investment portfolio, the organisation of custodial services, accounting, secretarial and administrative services, all of which are subject to Board oversight. The main issues reserved for the Board include:

- the appointment, evaluation, remuneration and removal of the Manager;
- the consideration and approval of future developments or changes to the investment policy, including risk and asset allocation;
- consideration of corporate strategy and corporate events that arise;
- application of the principles of the AIC Code, corporate governance and internal control;
- review of sub-committee recommendations, including the recommendation to shareholders for the appointment and remuneration of the Auditor;
- approving the Annual Report and Financial Statements, the Half-yearly Financial Report, the voluntary Interim Management Statements, net asset value updates (where required), and the associated announcements;
- approval of the dividend policy and payments of appropriate dividends to shareholders;
- the performance of the Company, including monitoring of the discount of share price to the net asset value;
- share buy-back and treasury share policies;
- participation in dividend re-investment schemes and Top Up Offers; and
- monitoring shareholder profile and considering shareholder communications.

Given the size, nature and complexity of the Company, the Board considers it unnecessary to establish a Management Engagement Committee.

It is the responsibility of the Board to present an Annual Report and Financial Statements that are fair, balanced and understandable, which provides the information necessary for shareholders to assess the position, performance, strategy and business model of the Company.

Committees' and Directors' performance evaluation

Performance of the Board and the Directors is assessed on the following:

- attendance at Board and Committee meetings;
- the contribution made by individual Directors at, and outside of, Board and Committee meetings; and
- completion of a detailed internal assessment process and annual performance evaluation conducted by the Chairman. The Senior Independent Director reviews the Chairman's annual performance evaluation.

The evaluation process has consistently identified that the Board works well together and has the right balance of independence, skills, experience and knowledge of the Company amongst the Directors. Diversity within the Board is achieved through the appointment of directors with different backgrounds and skills.

Directors are offered training, both at the time of joining the Board and on other occasions where required. The Directors attend external courses and industry events which provides further experience to help them fulfil their responsibilities. The Board also undertakes a proper and thorough evaluation of its committees on an annual basis.

In light of the structured performance of the individual Directors and the structured performance evaluation, James Agnew, Tony Ellingham, Pam Garside and Ian Spence, are considered to be effective Directors who demonstrate strong commitment to the role. The Board believes it to be in the best interest of the Company to re-appoint these Directors at the forthcoming AGM and has nominated them for re-election accordingly. For more details on the specific background, skills and experience of each Director, please see the Board of Directors section on pages 36 and 37.

Remuneration Committee

The Remuneration Committee consists of all Directors and Ian Spence is the Chairman. All Directors sit on the Remuneration Committee as their balance of skills and knowledge are relevant to the Committee's responsibilities. The Committee meets annually and held one formal meeting during the year with full attendance from all of its members at the time of the meeting.

The terms of reference for the Remuneration Committee can be found on the Company's webpage on the Manager's website at www.albion.capital/vct-funds/CRWN under the "Corporate Governance" section.

Audit and Risk Committee

The Audit and Risk Committee consists of all Directors and Tony Ellingham is the Chairman. In accordance with the AIC Code, members of the Audit and Risk Committee have recent and relevant financial experience, as well as experience relevant to the sector.

Given the size of the Board and the complexity of the business, James Agnew is both Chairman of the Board and a member of the Audit and Risk Committee as his background, skills and experience are relevant for the Committee's responsibilities. The Committee met twice during the year ended 30 June 2024.

The Independent Auditor, Johnston Carmichael, attended the Audit and Risk Committee meeting at which the Annual Report and Financial Statements for the year ended 30 June 2024 were discussed. Johnston Carmichael also met with the Audit and Risk Committee prior to the meeting without the presence of the Manager.

Written terms of reference have been constituted for the Audit and Risk Committee and can be found on the Company's webpage on the Manager's website at www.albion.capital/vct-funds/CRWN in the "Corporate Governance" section.

During the year under review, the Audit and Risk Committee discharged its responsibilities including:

- formally reviewing the Annual Report and Financial Statements and the Half-yearly Financial Report, with particular focus on the main areas requiring judgement and on critical accounting policies;
- reviewing the effectiveness of the internal controls system and examination of the Internal Controls Report produced by the Manager;
- meeting with the external Auditor, reviewing their findings and evaluating their performance;
- reviewing the performance of the Manager and making recommendations regarding their re-appointment to the Board;
- highlighting the key risks and specific issues relating to the Financial Statements including the reasonableness of valuations, compliance with accounting standards and UK law, corporate governance and listing and disclosure rules as well as going concern and viability statements. These issues were addressed through detailed review, discussion and challenge by the Board of these matters, as well as by reference to underlying technical information to back up the discussions. Taking into account risk factors that impact on the Company both as reflected in the annual accounts and in a detailed risk matrix, both of which are reviewed periodically in detail, including in the context of emerging risks;

- advising the Board on whether the Annual Report and Financial Statements, taken as a whole, is fair, balanced and understandable and provides the information necessary for shareholders to assess the Company's position, performance, business model and strategy; and
- reporting to the Board on how it has discharged its responsibilities.

The Committee also examines going concern and viability statements, using financial projections provided by the Manager on the Company and by examining the liquidity in the Company's portfolio, including cash and realisable investments, the committed costs of the Company and where liquidity might be found if required. The Audit and Risk Committee also receives regular reports on compliance with VCT status, which is subject to various internal controls and external review when investment commitments are made.

Financial Statements

The Audit and Risk Committee has initial responsibility for reviewing the Financial Statements and reporting on any significant issues that arise in relation to the audit of the Financial Statements as outlined below. Such issues were communicated with the external Auditor with the approval of the audit strategy and at the completion of the audit of the Financial Statements. No conflicts arose between the Audit and Risk Committee and the external Auditor in respect of their work during the year.

The key accounting and reporting issues considered by the Committee were:

The valuation of the Company's investments
Valuations of investments are prepared by the Manager. The Audit and Risk Committee reviewed the estimates and judgements made in relation to these investments and were satisfied that they were appropriate. The Committee also discussed the controls in place over the valuation of investments. The Committee recommended investment valuations to the Board for approval.

Revenue recognition
The revenue generated from loan stock interest and dividend income has been considered by the Audit and Risk Committee as part of its review of the Annual Report as well as a quarterly review of the management accounts prepared by the Manager. The Audit and Risk Committee has considered the controls in place over revenue recognition to ensure that amounts received are in line with expectation and budget.

Following detailed reviews of the Annual Report and Financial Statements and consideration of the key areas of risk identified, the Board as a whole have concluded that the Financial Statements are fair, balanced and understandable and that they provide the information necessary for shareholders to assess the Company's position, performance, business model and strategy.

Relationship with the External Auditor

The Audit and Risk Committee reviews the performance and continued suitability of the Company's external Auditor on an annual basis. They assess the external Auditor's independence, qualification, extent of relevant experience, effectiveness of audit procedures as well as the robustness of their quality assurance procedures. In advance of each audit, the Committee obtains confirmation from the external Auditor that they are independent and of the level of non-audit fees earned by them and their affiliates. No non-audit services were provided during the financial year ended 30 June 2024.

As part of its work, the Audit and Risk Committee has undertaken a formal evaluation of the external Auditor against the following criteria:

- Qualification
- Expertise
- Resources
- Effectiveness
- Independence
- Leadership

In order to form a view of the effectiveness of the external audit process, the Audit and Risk Committee took into account information from the Manager regarding the audit process, the formal documentation issued to the Audit and Risk Committee and the Board by the external Auditor regarding the external audit for the year ended 30 June 2024, and assessments made by individual Directors.

The Audit and Risk Committee also has an annual meeting with the external Auditor, without the Manager present, at which pertinent questions are asked to help the Audit and Risk Committee determine if the Auditor's skills and approach to the annual audit and issues that arise during the course of the audit match all the relevant and appropriate criteria for the audit to have been an effective and objective review of the company's year-end reporting.

Following the formal audit tender process in 2023, Johnston Carmichael were appointed as auditor in October 2023, which was approved at the last AGM. Johnston Carmichael will rotate the senior statutory auditor responsible for the audit every five years.

The Audit and Risk Committee has concluded that Johnston Carmichael is independent of the Company and recommended that a resolution for the re-appointment of Johnston Carmichael as the Company's Auditor should be put to the forthcoming Annual General Meeting.

Nomination Committee

The Nomination Committee consists of all Directors and James Agnew is the Chairman. All Directors sit on the Nomination Committee as their balance of skills and knowledge are relevant to the Committee's responsibilities. The terms of reference of the Nomination Committee are to evaluate the balance of skills, experience and time commitment of the current Board members and make recommendations to the Board as and when a particular appointment arises.

The Board's policy on the recruitment of new Directors is to attract a range of backgrounds, skills and experience and to ensure that appointments are made on the grounds of merit against clear and objective criteria and bear in mind gender and other diversity within the Board. The Board is also mindful of the importance of creating good working relationships within the Board and with external agents. The Nomination Committee reviews succession planning regularly which includes considering tenure of existing Board members and any potential skills gaps that might need to be addressed when Board membership changes.

The Nomination Committee held one formal meeting during the year. As the Board underwent succession planning, there had been a number of sessions to discuss the succession plan, with Penny Freer retiring after the last AGM and James Agnew becoming the Chairman.

The terms of reference for the Nomination Committee can be found on the Company's webpage on the Manager's website at www.albion.capital/vct-funds/CRWN in the "Corporate Governance" section.

Internal control

In accordance with the AIC Corporate Governance Code, the Board has an established process for identifying, evaluating and managing the significant risks faced by the Company. This process has been in place throughout the year and continues to be subject to regular review by the Board in accordance with the FRC guidance "Risk Management, Internal Control and Related Financial and Business Reporting". The Board is responsible for the Company's system of internal control and for reviewing its effectiveness. However, acknowledging that such a system is designed to manage, rather than eliminate the risks of failure to achieve the Company's business objectives and can only provide reasonable and not absolute assurance against material misstatement or loss.

The Board, assisted by the Audit and Risk Committee, monitors all controls, including financial, operational and compliance controls, and risk management. The Audit and Risk Committee receives each year from the Manager a formal report, which details the steps taken to monitor the areas of risk, including those that are not directly the responsibility of the Manager, and which reports the details of any known internal control failures. Steps continue to be taken to embed the system of internal control and risk management into the operations and culture of the Company and its key suppliers, and to deal with areas of improvement which come to the Manager's and the Audit and Risk Committee's attention.

The Board, through the Audit and Risk Committee, has performed a specific assessment for the purpose of this Annual Report. This assessment considers all significant aspects of internal control arising during the year. The Audit and Risk Committee assists the Board in discharging its review responsibilities.

The main features of the internal control system with respect to financial reporting, implemented throughout the year are:

- segregation of duties between the preparation of valuations and recording into the accounting records;



- reviews of valuations are carried out by the Valuation Committee and reviews of financial reports are carried out by the Senior Finance personnel and the Operations Partner of Albion Capital Group LLP;
- independent third party valuations of the majority of the asset-based investments within the portfolio are undertaken annually;
- bank reconciliations are carried out monthly by the Manager;
- all published financial reports are reviewed by the Manager's Compliance department;
- the Board reviews financial information; and
- a separate Audit and Risk Committee of the Company reviews financial information (including the valuations) to be published.

As the Board has delegated the investment management and administration to Albion Capital Group LLP, the Board feels that it is not necessary to have its own internal audit function. Instead, the Board has access to Azets, which, as internal auditor for Albion Capital Group LLP, undertakes periodic examination of the business processes and controls environment at Albion Capital Group LLP, and ensures that any recommendations to implement improvements in controls are carried out. During the year, the Audit and Risk Committee and the Board reviewed internal audit reports prepared by Azets. The Audit and Risk Committee Chairman was able to ask specific and detailed questions of Azets. The Board will continue to monitor its system of internal control in order to provide assurance that it operates as intended.

In addition to this, Ocorian Depositary (UK) Limited, the Company's external Depositary, provides cash monitoring, asset verification, and oversight services to the Company and reports to the Board on a quarterly basis. The Board and the Audit and Risk Committee will continue to monitor its system of internal control in order to provide assurance that it operates as intended.

Conflicts of interest

Directors review the disclosure of conflicts of interest annually. In addition, any changes are reviewed and noted at the beginning of each Board meeting. A Director who has conflicts of interest has two independent Directors authorise those conflicts, and is excluded from discussions or decisions regarding those conflicts. Procedures to disclose and authorise conflicts of interest have been adhered to throughout the year.

Capital structure and Articles of Association

Details regarding the Company's capital structure, substantial interests and Directors' powers to buy and issue shares are detailed in full on page 45 of the Directors' report. The Company is not party to any significant agreements that may take effect, alter or terminate upon a change of control of the Company following a takeover bid.

Any amendments to the Company's Articles of Association are by way of a special resolution subject to ratification by shareholders.

Relationships with shareholders

The Company's AGM is being held virtually on 26 November 2024. The AGM will include a presentation from the Manager on the portfolio and on the Company, as well as answering questions that shareholders may have.

The next Shareholder Seminar will be held at 11 Cavendish Square, London, W1G 9EB on 20 November 2024. The Board and Manager are keen to interact with shareholders and look forward to sharing with you further portfolio updates. Places are limited and to reserve a place please email info@albion.capital with subject heading "Shareholder Seminar" and include your full name. You will receive an email confirmation of your place, subject to availability.

Shareholders and financial advisers are able to obtain information on holdings and performance using the contact details provided on page 4.

The Company's share buy-back programme operates in the market through brokers. In order to sell shares, as they are quoted on the London Stock Exchange, investors should approach a broker to undertake the sale. Banks may be able to assist shareholders with a referral to a broker within their banking group. More information on share buy-backs can be found in the Chairman's statement on page 12.

Statement of compliance

The Directors consider that the Company has complied throughout the year ended 30 June 2024 with all the relevant provisions set out in the AIC Code issued in 2019. By reporting against the AIC Code, the Board are meeting their obligations in relation to the 2018 UK Corporate Governance Code (and associated disclosure requirements under paragraph 6.6.6 of the UK Listing Rules). The Directors also consider that they are complying with their statutory responsibilities and other regulatory provisions which have a bearing on the Company.

For and on behalf of the Board

James Agnew
Chairman
24 October 2024

DIRECTORS' REMUNERATION REPORT

Introduction

This report is submitted in accordance with Section 420 of the Companies Act 2006 and describes how the Board has applied the principles relating to the Directors' remuneration.

An Ordinary resolution will be proposed at the Annual General Meeting of the Company to be held on 26 November 2024 for the approval of the Director's Annual Remuneration Report as set out below.

The current Remuneration Policy was approved by shareholders (of shareholders who cast their vote, 96.9% voted for the resolution, 3.1% against the resolution and of the total votes cast, 535,379, being 0.2% of total voting rights, were withheld) at the AGM held on 22 November 2023. It will remain in place for a three year period, and it will next be put to shareholders at the 2026 AGM.

The Company's independent Auditor, Johnston Carmichael LLP, is required to give its opinion on certain information included in this report, as indicated below. The Auditor's opinion is included in the Independent Auditor's Report.

Annual statement from the Chairman of the Remuneration Committee

The Remuneration Committee comprises all of the Directors, with Ian Spence as Chairman.

The Remuneration Committee met after the year end to review Directors' responsibilities and fees against the market and concluded that the current level of remuneration, which was last increased from 1 July 2023, remained appropriate and so proposed no increase for the forthcoming year.

Directors' remuneration policy

The Company's policy is that fees payable to non-executive Directors should reflect their expertise, responsibilities and time spent on Company matters and should be sufficient to enable candidates of high calibre to be recruited. In determining the level of non-executive remuneration, market equivalents are considered in comparison to the overall activities and size of the Company. There are no performance related pay criteria applicable to non-executive Directors.

The current maximum level of non-executive Directors' remuneration is £150,000 per annum in aggregate which is fixed by the Company's Articles of Association, changes to which are made by ordinary resolution.

The AIC Code requires that all Directors submit themselves for re-election annually, therefore James Agnew, Tony Ellingham, Pam Garside and Ian Spence will offer themselves for re-election.

None of the Directors have a service contract with the Company, and as such there is no policy on termination payments. There is no notice period and no payments for loss of office were made during the year. On being appointed to the Board, Directors receive a letter from the Company setting out the terms of their appointment and their specific duties and responsibilities, which are kept at the Manager's registered address. The Company is managed by Albion Capital Group LLP and has no employees. The Board consists solely of non-executive Directors, who are considered key management personnel.

Shareholders' views in respect of Directors' remuneration are regarded highly and the Board encourages shareholders to participate in its Annual General Meeting in order to communicate their thoughts to the Board, which it takes into account where appropriate when formulating its policy. At the last AGM, 97.4% of shareholders who voted, voted for the resolution approving the Directors' remuneration report, 2.6% of shareholders voted against the resolution and of the total votes cast, 472,131 were withheld (being 0.2% of total voting rights), which shows significant shareholder support from those who voted.

Annual report on remuneration

The remuneration of individual Directors' is determined by the Remuneration Committee within the framework set by the Board and the Committee meets at least once a year.

The Board is responsible for reviewing the remuneration of the Directors and the Company's remuneration policy to ensure that it reflects the duties, responsibilities and value of time spent by the Directors on the business of the Company and makes recommendations to the Board accordingly.

Directors' remuneration

The Director's remuneration and interests in the shares of the Company which are shown in the tables below have been audited.

The following tables show an analysis of the remuneration, excluding National Insurance, of individual Directors who served during the last four years.

The base remuneration of each of the Directors' positions increased during the year, effective from 1 July 2023.

The changes from 2023 to 2024 reflect the increase in the base remuneration from 22 November 2023. The changes from 2021 to 2022 are a result of the increase of the base remuneration of each of the Directors' positions part way through that year. The large change from 2020 to 2021 is due to Ian Spence's fees being pro-rated in 2020 as he joined the Board part way through that year.

The Directors' remuneration for the year ending 30 June 2025 is expected to be approximately £112,000.

In addition to Directors' remuneration, the Company paid an annual premium in respect of Directors' & Officers' Liability Insurance of £28,864 (2023: £26,256).

The Company does not confer any share options, long term incentives or retirement benefits to any Director, nor does it make a contribution to any pension scheme on behalf of the Directors. There are therefore no variable elements to the Directors' remuneration.

Each Director of the Company was remunerated personally through the Manager's payroll, which has been recharged to the Company.

Total Directors' remuneration (audited)

	30 June 2024 **£**	30 June 2023 £
James Agnew	**30,200**	25,500
Tony Ellingham	**23,500**	-
Pam Garside	**26,000**	23,500
Ian Spence	**26,000**	23,500
Penny Freer (retired 22 November 2023)	**12,200**	27,500
	117,900	100,000

Annual percentage change in Directors' remuneration

	Percentage change 2023 to 2024 **%**	Percentage change 2022 to 2023 %	Percentage change 2021 to 2022 %	Percentage change 2020 to 2021 %	Percentage change 2019 to 2020 %
James Agnew	**19**	3	8	1	6
Tony Ellingham (appointed 1 September 2023)	**n/a**	n/a	n/a	n/a	n/a
Pam Garside	**11**	2	5	-	201
Ian Spence (appointed 1 May 2020)	**11**	2	5	500	n/a
Penny Freer (retired 22 November 2023)	**n/a**	3	13	7	2
Richard Huntingford (retired 30 September 2020)	**n/a**	n/a	n/a	(75)	-
	18	2	1	(3)	3

Directors interests (audited)

The Directors and their interests in the shares of the Company (together with those of their immediate family) are shown below.

	Shares held as at 30 June 2024	Shares held as at 30 June 2023
James Agnew	**92,843**	88,209
Tony Ellingham	**31,948**	-
Pam Garside	**108,617**	103,195
Ian Spence	**39,171**	37,216
	272,579	228,620

There are no guidelines or requirements in respect of Directors' share holdings.

There have been no changes in the holdings of the Directors between 30 June 2024 and the date of this report.

Albion Capital Group LLP, its partners and staff hold a total of 2,616,256 shares in the Company as at 30 June 2024.

Performance graph

The graph that follows shows the Company's Ordinary share price total return against the FTSE All-Share Index total return, in both instances with dividends reinvested. The Directors consider the FTSE All-Share Index to be the most appropriate benchmark for the Company as it contains a large range of sectors within the UK economy. Investors should, however, be reminded that shares in VCTs generally trade at a discount to the actual net asset value of the Company.

There are no options, issued or exercisable, in the Company which would distort the graphical representation.

Share price total return relative to FTSE All-Share Index total return
(in both cases with dividends reinvested)



Methodology: The share price total return to the shareholder, including original amount invested (rebased to 100), assuming that dividends were reinvested at the share price of the Company at the time the shares were quoted ex-dividend. Transaction costs are not taken into account.

Directors' pay compared to distribution to shareholders

	2024 £'000	2023 £'000	Percentage change 2023 to 2024 %
Total dividend distribution to shareholders	**4,514**	4,237	**7**
Share buybacks	**2,562**	2,359	**9**
Total Directors' fees (excluding NIC)	**118**	100	**18**

For and on behalf of the Board

James Agnew
Chairman
24 October 2024

INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF ALBION CROWN VCT PLC

Opinion

We have audited the financial statements of Albion Crown VCT PLC ("the Company"), for the year ended 30 June 2024, which comprise the Income statement, the Balance sheet, the Statement of changes in equity, the Statement of cash flows, and the notes to the financial statements, including significant accounting policies.

The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of Company's affairs as at 30 June 2024 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report.

We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, as applied to listed public interest entities, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our approach to the audit

We planned our audit by first obtaining an understanding of the Company and its environment, including its key activities delegated by the Board to relevant approved third-party service providers and the controls over provision of those services.

We conducted our audit using information maintained and provided by Albion Capital Group LLP (the "Manager", the "Company Secretary," and "Administrator") Ocorian Depositary (UK) Limited (the "Depositary") and Computershare Investor Services PLC (the "Registrar") to whom the Company has delegated the provision of services.

We tailored the scope of our audit to reflect our risk assessment, taking into account such factors as the types of investments within the Company, the involvement of the Administrator, the accounting processes and controls, and the industry in which the Company operates.

The scope of our audit was influenced by our application of materiality. We set certain quantitative thresholds for materiality. These together with qualitative considerations, helped us to determine the scope of our audit and the nature, timing and extent of our audit procedures on the individual financial statement line items and disclosures and in the evaluation of the effect of misstatements, both individually and in aggregate on the financial statements as a whole.

Key audit matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period and include the most significant assessed risks of material misstatement (whether or not due to fraud) that we identified. These matters included those which had the greatest effect on: the overall audit strategy; the allocation of resources in the audit; and directing the efforts of the engagement team. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, we do not provide a separate opinion on these matters.

We summarise below the key audit matter in arriving at our audit opinion above, together with how our audit addressed this matter and the results of our audit work in relation to this matter.

Key audit matter	How our audit addressed the key audit matter and our conclusions
Valuation of level 3 investments (as per page 57 (Audit and Risk Committee Report), pages 77 and 78 (Accounting Policies) and Note 11.) The valuation of the level 3 portfolio at 30 June 2024 was £77.62m (2023 £67.74m). As this is the largest component of the Company's Balance sheet, and there is a high degree of estimation and subjectivity in the valuation of level 3 investments, it has been designated as a key audit matter, being one of the most significant assessed risks of material misstatements due to fraud or error. The level 3 investments are valued in accordance with the revised International Private Equity and Venture Capital (IPEV) valuation guidelines. Significant judgement is required in applying these principles and determining certain inputs to the valuation models.	We have performed a walkthrough of the level 3 investment valuation process to evaluate the design of the process and implementation of key controls. We obtained evidence that the Manager's Valuation Committee review and approve the valuation of the level 3 investments. We obtained evidence of the Board's review and approval of the valuation of the level 3 investments. We stratified the portfolio of level 3 investments according to risk, considering the value of individual investments, the movement in fair value and the inherent risk factors associated with each valuation basis. We then selected a sample of investments for testing, to ensure appropriate coverage of each strata of the portfolio. For the sample of level 3 investments, we: • Obtained an understanding of the sector for each investee company for the period being audited, making enquiries of management. • Assessed the degree to which the valuations are subject to estimation uncertainty and the degree to which the selection and application of the valuation method, assumptions and data are affected by complexity and subjectivity, to understand the specific risks of each valuation. • Based on the specific risks identified, for certain investments in our sample, we engaged our specialist corporate finance team, to challenge the appropriateness of certain judgements, such as multiples and discounts. • Corroborated data used in the valuation models to independent sources, assessing if market conditions meet management's expectations and any forecasts used in the valuation models are suitable, consistent and the data is relevant and reliable, including considering any contradictory data identified. • Reperformed the calculation of the valuation models to ensure mathematical accuracy. • Assessed whether the valuation methodologies were in line with the accounting policies, FRS 102 and IPEV guidelines. • Where appropriate based on the valuation methodology applied, we developed an auditor's point estimate or range. We performed back-testing over investment disposals (proceeds vs most recent valuation) to assess for potential management bias in the valuation process. From our completion of these procedures, we identified no material misstatements in relation to the valuation of the level 3 investments.

Our application of materiality

We define materiality as the magnitude of misstatement in the financial statements that makes it probable that the economic decisions of a reasonably knowledgeable person would be changed or influenced. We use materiality in determining the nature and extent of our work and in evaluating the results of that work.

Materiality measure	Value
Materiality for the financial statements as a whole – we have set materiality as 2% of net assets as we believe that net assets is the primary performance measure used by investors and is the key driver of shareholder value. We determined the measurement percentage to be commensurate with the risk and complexity of the audit and the Company's listed status.	**£1.94m**
Performance materiality – performance materiality represents amounts set by the auditor at less than materiality for the financial statements as a whole, to reduce to an appropriately low level the probability that the aggregate of uncorrected and undetected misstatements exceeds materiality for the financial statements as a whole. In setting this we consider the Company's overall control environment and any experience of the audit that indicates a lower risk of material misstatements. Based on our judgements of these factors we have set performance materiality at 50% of our overall financial statement materiality as this is our first year as auditor.	**£0.97m**
Specific materiality - recognising that there are transactions and balances of a lesser amount which could influence the understanding of users of the financial statements we calculate a lower level of materiality for testing such areas. Specifically, given the importance of the distinction between revenue and capital for the Company, we applied a separate testing threshold for the revenue column of the income statement set at the higher of 5% of the revenue profit on ordinary activities before taxation and our Audit and Risk Committee reporting threshold. We have also set a separate materiality in respect of related party transactions and Directors' remuneration. We used our judgement in setting these thresholds and considered our experience and industry benchmarks for specific materiality.	**£0.10m**
Audit and Risk Committee reporting threshold – we agreed with the Audit and Risk Committee that we would report to them all differences in excess of 5% of overall materiality in addition to other identified misstatements that warranted reporting on qualitative grounds, in our view. For example, an immaterial misstatement as a result of fraud.	**£0.10m**

During the course of the audit, we reassessed initial materiality and found no reason to alter the basis of calculation used at year-end.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Our evaluation of the Directors' assessment of the Company's ability to continue to adopt the going concern basis of accounting included:

- Evaluating management's method of assessing going concern, including consideration of market conditions and uncertainties;
- Assessing and challenging the forecast cashflows and associated sensitivity modelling used by the Directors in support of their going concern assessment;
- Obtaining and recalculating management's assessment of the Company's ongoing maintenance of venture capital trust status; and
- Assessing the adequacy of the Company's going concern disclosures included in the Annual Report.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

In relation to the Company's reporting on how it has applied the UK Corporate Governance Code, we have nothing material to add or draw attention to in relation to the Directors' statement in the financial statements about whether the Directors considered it appropriate to adopt the going concern basis of accounting.

Our responsibilities and the responsibilities of the Directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the Annual Report other than the financial statements and our auditor's report thereon. The Directors are responsible for the other information contained within the Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, the part of the Directors' Remuneration Report to be audited has been properly prepared in accordance with the Companies Act 2006.

In our opinion, based on the work undertaken in the course of the audit:

- The information given in the Strategic Report and the Directors' Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- The Strategic Report and the Directors' Report have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the Company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Directors' Report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- Adequate accounting records have not been kept by the Company, or returns adequate for our audit have not been received from branches not visited by us; or
- The financial statements and the part of the Directors' Remuneration Report to be audited are not in agreement with the accounting records and returns; or
- Certain disclosures of Directors' remuneration specified by law are not made; or
- We have not received all the information and explanations we require for our audit; or
- A corporate governance statement has not been prepared by the Company.

Corporate governance statement

The UK Listing Rules require us to review the Directors' statement in relation to going concern, longer-term viability and that part of the Corporate Governance Statement relating to the Company's compliance with the provisions of the UK Corporate Governance Code specified for our review.

Based on the work undertaken as part of our audit, we have concluded that each of the following elements of the Corporate Governance Statement is materially consistent with the financial statements or our knowledge obtained during the audit:

- The Directors' statement with regards to the appropriateness of adopting the going concern basis of accounting and any material uncertainties identified set out on page 46;
- The Directors' explanation as to its assessment of the Company's prospects, the period this assessment covers and why the period is appropriate set out on page 26;
- The Directors' statement on whether it has a reasonable expectation that the Company will be able to continue in operation and meet its liabilities set out on page 26;
- The Directors' statement on fair, balanced and understandable set out on page 53;
- The Board's confirmation that it has carried out a robust assessment of the emerging and principal risks set out on page 26;
- The section of the annual report that describes the review of the effectiveness of risk management and internal control systems set out on pages 58 and 59; and
- The section describing the work of the Audit and Risk Committee set out on pages 56 to 58.

Responsibilities of Directors

As explained more fully in the Directors' responsibilities statement set out on page 53, the Directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: http://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

We assessed whether the engagement team collectively had the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations by considering their experience, past performance and support available.

All engagement team members were briefed on relevant identified laws and regulations and potential fraud risks at the planning stage of the audit. Engagement team members were reminded to remain alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

We obtained an understanding of the legal and regulatory frameworks that are applicable to the Company and the sector in which it operates, focusing on those provisions that had a direct effect on the determination of material amounts and disclosures in the financial statements. The most relevant frameworks we identified include:

- Companies Act 2006;
- FCA listing and DTR rules;
- The principles of the UK Corporate Governance Code applied by the AIC Code of Corporate Governance (the "AIC Code");

- Industry practice represented by the Statement of Recommended Practice: financial statements of Investment Trust Companies and Venture Capital Trusts ("the SORP");
- Financial Reporting Standard 102; and
- The Company's qualification as a Venture Capital Trust under section 274 of the Income Tax Act 2007.

We gained an understanding of how the Company is complying with these laws and regulations by making enquiries of management and those charged with governance. We corroborated these enquiries through our review of relevant correspondence with regulatory bodies and board meeting minutes.

We assessed the susceptibility of the Company's financial statements to material misstatement, including how fraud might occur, by meeting with management and those charged with governance to understand where it was considered there was susceptibility to fraud. This evaluation also considered how management and those charged with governance were remunerated and whether this provided an incentive for fraudulent activity. We considered the overall control environment and how management and those charged with governance oversee the implementation and operation of controls. We identified a heightened fraud risk in relation to the valuation of level 3 investments (audit procedures performed in response to this risk are set out in the section on key audit matters above) and management override of controls (procedures performed in response to this risk are included below).

In addition to the above, the following procedures were performed to provide reasonable assurance that the financial statements were free of material fraud or error:

- Reviewing minutes of meetings of those charged with governance for reference to: breaches of laws and regulation or for any indication of any potential litigation and claims; and events or conditions that could indicate an incentive to commit fraud or provide an opportunity to commit fraud;
- Performing audit work procedures over the risk of management override of controls, including unpredictability testing, testing of journal entries and other adjustments for appropriateness, recalculating the investment management and performance incentive fees, evaluating the business rationale of significant transactions outside the course of normal business and reviewing judgements made by management in their calculation of accounting estimates for potential management bias;
- Completion of appropriate checklists and use of our experience to assess the Company's compliance with the Companies Act 2006 and the UK Listing Rules; and
- Agreement of the financial statement disclosures to supporting documentation.

Our audit procedures were designed to respond to the risk of material misstatements in the financial statements, recognising that the risk of not detecting a material misstatement due to fraud is higher than the



risk of not detecting one resulting from error, as fraud may involve intentional concealment, forgery, collusion, omission or misrepresentation. There are inherent limitations in the audit procedures described above and the further removed non-compliance with laws and regulations is from the events and transactions reflected in the financial statements, the less likely we would become aware of it.

Other matters which we are required to address

Following the recommendation of the Audit and Risk Committee, we were appointed by the Board on 30 October 2023 to audit the financial statements for the year ended 30 June 2024 and subsequent financial periods. The period of our total uninterrupted engagement is one year, covering the year ended 30 June 2024.

The non-audit services prohibited by the FRC's Ethical Standard were not provided to the Company and we remain independent of the Company in conducting our audit.

Our audit opinion is consistent with the additional report to the Audit and Risk Committee.

Use of our report

This report is made solely to the Company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the Company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company and the Company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Bryan Shepka (Senior Statutory Auditor)
For and on behalf of Johnston Carmichael LLP
Statutory Auditor
Edinburgh, United Kingdom
25 October 2024

Company information and Financials



INCOME STATEMENT

		Year ended 30 June 2024			Year ended 30 June 2023		
		Revenue	**Capital**	**Total**	Revenue	Capital	Total
	Note	**£'000**	**£'000**	**£'000**	£'000	£'000	£'000
Gain on investments	3	**-**	**2,817**	**2,817**	-	3,846	3,846
Investment income	4	**1,458**	**-**	**1,458**	936	-	936
Investment Manager's fees	5	**(160)**	**(1,438)**	**(1,598)**	(153)	(1,380)	(1,533)
Other expenses	6	**(512)**	**-**	**(512)**	(432)	-	(432)
Profit on ordinary activities before tax		**786**	**1,379**	**2,165**	351	2,466	2,817
Tax on ordinary activities	8	**-**	**-**	**-**	-	-	-
Profit and total comprehensive income attributable to shareholders		**786**	**1,379**	**2,165**	351	2,466	2,817
Basic and diluted earnings per Ordinary share (pence)*	10	**0.27**	**0.48**	**0.75**	0.13	0.92	1.05

* adjusted for treasury shares

The accompanying notes on pages 77 to 91 form an integral part of these Financial Statements.

The total column of this Income statement represents the profit and loss account of the Company. The supplementary revenue and capital columns have been prepared in accordance with The Association of Investment Companies Statement of Recommended Practice.

All gains and losses are recognised in the Income statement and all items in the above statement are derived from continuing operations.



BALANCE SHEET

	Note	30 June 2024 £'000	30 June 2023 £'000
Fixed asset investments	11	**77,679**	68,000
Current assets			
Trade and other receivables	13	**60**	1,684
Cash in bank and at hand		**22,089**	25,006
		22,149	26,690
Creditors: amounts falling due within one year			
Other creditors		**(2,210)**	-
Trade and other payables less than one year	14	**(574)**	(721)
		(2,784)	(721)
Net current assets		**19,365**	25,969
Total assets less current liabilities		**97,044**	93,969
Equity attributable to equity holders			
Called up share capital	15	**3,472**	3,269
Share premium		**-**	47,067
Capital redemption reserve		**60**	-
Unrealised capital reserve		**30,237**	26,402
Realised capital reserve		**6,721**	9,177
Other distributable reserve		**56,554**	8,054
Total equity shareholders' funds		**97,044**	93,969
Basic and diluted net asset value per share (pence)*	16	**32.20**	33.13

* excluding treasury shares

The accompanying notes on pages 77 to 91 form an integral part of these Financial Statements.

These Financial Statements were approved by the Board of Directors, and authorised for issue on 24 October 2024 and were signed on its behalf by

James Agnew
Chairman

Company number: 03495287

STATEMENT OF CHANGES IN EQUITY

	Called up share capital £'000	Share premium £'000	Capital redemption reserve £'000	Unrealised capital reserve £'000	Realised capital reserve* £'000	Other distributable reserve* £'000	Total £'000
As at 1 July 2023	3,269	47,067	-	26,402	9,177	8,054	93,969
Profit and total comprehensive income	-	-	-	3,089	(1,710)	786	2,165
Transfer of previously unrealised losses on disposal of investments	-	-	-	746	(746)	-	-
Dividends paid	-	-	-	-	-	(4,514)	(4,514)
Purchase of shares for treasury (including costs)	-	-	-	-	-	(791)	(791)
Purchase of shares for cancellation (including costs)	(60)	-	60	-	-	(1,770)	(1,770)
Issue of equity	263	7,973	-	-	-	-	8,236
Cost of issue of equity	-	(251)	-	-	-	-	(251)
Cancellation of share premium**	-	(54,789)	-	-	-	54,789	-
As at 30 June 2024	3,472	-	60	30,237	6,721	56,554	97,044
As at 1 July 2022	2,905	35,522	-	20,384	12,729	14,299	85,839
Profit and total comprehensive income	-	-	-	3,803	(1,337)	351	2,817
Transfer of previously unrealised losses on disposal of investments	-	-	-	2,216	(2,216)	-	-
Dividends paid	-	-	-	-	-	(4,237)	(4,237)
Purchase of shares for treasury (including costs)	-	-	-	-	-	(2,359)	(2,359)
Issue of equity	364	11,854	-	-	-	-	12,218
Cost of issue of equity	-	(309)	-	-	-	-	(309)
As at 30 June 2023	3,269	47,067	-	26,402	9,177	8,054	93,969

* Included within these reserves is an amount of £19,247,000 (2023: £12,804,000) which is considered distributable. Over the next four years a further £41,423,000 will become distributable. This is due to the HMRC requirement that the Company cannot use capital raised in the past three years to make a payment or distribution to shareholders. On 1 July 2024, £9,645,000 became distributable in line with this.

** During the year, the Company obtained authority to cancel the amount standing to the credit of its share premium reserve at the Annual General Meeting on 22 November 2023. The purpose of the proposal was to increase the distributable reserves available to the Company for the payment of dividends, the buy-back of shares, and for other corporate purposes. Further details can be found in the Directors' report on page 50.

The nature of each reserve is described in note 2 on pages 78 and 79.

STATEMENT OF CASH FLOWS

	Year ended 30 June 2024 £'000	Year ended 30 June 2023 £'000
Cash flow from operating activities		
Loan stock income received	**710**	550
Dividend income received	**128**	39
Income from fixed term funds received	**357**	145
Deposit interest received	**351**	138
Investment Manager's fees paid	**(1,585)**	(2,081)
Other cash payments	**(497)**	(425)
Corporation tax paid	**-**	-
Net cash flow generated from operating activities	**(536)**	(1,634)
Cash flow from investing activities		
Purchase of fixed asset investments*	**(9,523)**	(7,870)
Proceeds from disposals of fixed asset investments*	**4,185**	1,139
Funds held pending legal completion of sale**	**2,210**	-
Net cash flow generated from investing activities	**(3,128)**	(6,731)
Cash flow from financing activities		
Issue of share capital	**7,290**	11,226
Cost of issue of equity***	**(40)**	(37)
Equity dividends paid (net of Dividend Reinvestment Scheme)	**(3,764)**	(3,517)
Purchase of own shares for treasury and cancellation (including costs)	**(2,739)**	(2,325)
Net cash flow generated from financing activities	**747**	5,347
(Decrease)/increase in cash in bank and at hand	**(2,917)**	(3,018)
Cash in bank and at hand at the start of the year	**25,006**	28,024
Cash in bank and at hand at the end of the year	**22,089**	25,006

* Purchases and disposals detailed above do not agree to note 11 due to restructuring of investments, conversion of convertible loan stock and settlement receivables and payables.

**This amount of £2,210,000 relates to the sale of Egress Software Technologies which completed on 1 July 2024 and was held as a creditor at 30 June 2024 as shown in note 14.

*** The cost of issue of equity does not agree to the Statement of changes in equity due to prospectus fundraising amounts being received net of fees.

NOTES TO THE FINANCIAL STATEMENTS

1. Basis of preparation

The Financial Statements have been prepared in accordance with applicable United Kingdom law and accounting standards, including Financial Reporting Standard 102 ("FRS 102"), and with the Statement of Recommended Practice "Financial Statements of Investment Trust Companies and Venture Capital Trusts" ("SORP") issued by The Association of Investment Companies ("AIC"). The Financial Statements have been prepared on a going concern basis and further details can be found in the Directors' report on page 46.

The preparation of the Financial Statements requires management to make judgements and estimates that affect the application of policies and reported amounts of assets, liabilities, income and expenses. The most critical estimates and judgements relate to the determination of carrying value of investments at Fair Value Through Profit and Loss ("FVTPL") in accordance with FRS 102 sections 11 and 12. The Company values investments by following the International Private Equity and Venture Capital Valuation ("IPEV") Guidelines as updated in 2022 and further detail on the valuation techniques used are outlined below.

Company information can be found on page 4.

2. Accounting policies

Fixed asset investments

The Company's business is investing in financial assets with a view to profiting from their total return in the form of income and capital growth. This portfolio of financial assets is managed, and its performance evaluated on a fair value basis, in accordance with a documented investment policy, and information about the portfolio is provided internally on that basis to the Board.

In accordance with the requirements of FRS 102, those undertakings in which the Company holds more than 20% of the equity as part of an investment portfolio are not accounted for using the equity method. In these circumstances the investment is measured at FVTPL.

Upon initial recognition (using trade date accounting) investments, including loan stock, are classified by the Company as FVTPL and are included at their initial fair value, which is cost (excluding expenses incidental to the acquisition which are written off to the Income statement).

Subsequently, the investments are valued at 'fair value', which is measured as follows:

- Investments listed on recognised exchanges are valued at their bid prices at the end of the accounting period or otherwise at fair value based on published price quotations.
- Unquoted investments, where there is no active market, are valued using an appropriate valuation technique in accordance with the IPEV Guidelines. Indicators of fair value are derived using established methodologies including: earnings multiples, revenue multiples, the level of third party offers received, cost or price of recent investment rounds, net assets, discounted cash flows and industry valuation benchmarks. Where price of recent investment is used as a starting point for estimating fair value at subsequent measurement dates, this has been benchmarked using an appropriate valuation technique permitted by the IPEV guidelines.
- In situations where cost or price of recent investment is used, consideration is given to the circumstances of the portfolio company since that date in determining fair value. This includes consideration of whether there is any evidence of deterioration or strong definable evidence of an increase in value. In the absence of these indicators, the investment in question is valued at the amount reported at the previous reporting date. Examples of events or changes that could indicate a diminution include:
  – the performance and/or prospects of the underlying business are significantly below the expectations on which the investment was based; or
  – a significant adverse change either in the portfolio company's business or in the technological, market, economic, legal or regulatory environment in which the business operates; or

– market conditions have deteriorated, which may be indicated by a fall in the share prices of quoted businesses operating in the same or related sectors.

Investments are recognised as financial assets on legal completion of the investment contract and are de-recognised on legal completion of the sale of an investment.

Dividend income is not recognised as part of the fair value movement of an investment, but is recognised separately as investment income through the other distributable reserve when a share becomes ex-dividend.

Current assets and payables

Receivables (including debtors due after more than one year), payables and cash are carried at amortised cost, in accordance with FRS 102. Deferred consideration meets the definition of a financing transaction held at amortised cost, and interest will be recognised through capital over the credit period using the effective interest method. There are no financial liabilities other than payables.

Investment income

Dividend income

Dividend income is included in revenue when the investment is quoted ex-dividend.

Unquoted loan stock income

Fixed returns on non-equity shares and debt securities are recognised when the Company's right to receive payment and expected settlement is established. Where interest is rolled up and/or payable at redemption then it is recognised as income unless there is reasonable doubt as to its receipt.

Fixed term funds income

Income from fixed term funds is recognised on an accruals basis using the agreed rate of interest.

Bank deposit income

Interest is recognised on an accruals basis using the rate of interest agreed with the bank.

Investment management fee, performance incentive fee and other expenses

All expenses have been accounted for on an accruals basis. Expenses are charged through the other distributable reserve except the following which are charged through the realised capital reserve:

- 90% of management fees and 100% of performance incentive fees, if any, are allocated to the realised capital reserve; and
- expenses which are incidental to the purchase or disposal of an investment are charged through the realised capital reserve.

Taxation

Taxation is applied on a current basis in accordance with FRS 102. Current tax is tax payable (refundable) in respect of the taxable profit (tax loss) for the current period or past reporting periods using the tax rates and laws that have been enacted or substantively enacted at the financial reporting date. Taxation associated with capital expenses is applied in accordance with the SORP.

Deferred tax is provided in full on all timing differences at the reporting date. Timing differences are differences between taxable profits and total comprehensive income as stated in the Financial Statements that arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in the Financial Statements. As a VCT, the Company has an exemption from tax on capital gains. The Company intends to continue meeting the conditions required to obtain approval as a VCT for the foreseeable future. The Company, therefore, should have no material deferred tax timing differences arising in respect of the revaluation or disposal of investments and the Company has not provided for any deferred tax.

Reserves

Called-up share capital

This accounts for the nominal value of the Company's shares.

Share premium

This accounts for the difference between the price paid for the Company's shares and the nominal value of those shares, less issue costs and transfers on cancellation of share premium once consent of the court is given.

During the year, the Company obtained authority to cancel the amount standing to the credit of its share premium reserve at the Annual General Meeting on 22 November 2023. The purpose of the proposal was to increase the distributable reserves available to the Company for the payment of dividends, the buy-back of shares, and for other corporate purposes. Further details can be found in the Directors' report on page 50.

Capital redemption reserve
This reserve accounts for amounts by which the issued share capital is diminished through the repurchase and cancellation of the Company's own shares, less any transfers on cancellation of capital redemption reserve; amounts are recognised once consent of the court has been given.

Unrealised capital reserve
Increases and decreases in the valuation of investments held at the year end against cost or previously recorded fair value are included in this reserve.

Realised capital reserve
The following are disclosed in this reserve:

- gains and losses compared to cost on the realisation of investments, or permanent diminutions in value (including gains recognised on the realisation of investments where consideration is deferred that are not distributable as a matter of law);
- finance income in respect of the unwinding of the discount on deferred consideration that is not distributable as a matter of law;
- expenses, together with the related taxation effect, charged in accordance with the above policies; and
- dividends paid to equity holders where paid out by capital.

Other distributable reserve
The special reserve, treasury share reserve and the revenue reserve were combined in 2012 to form a single reserve named other distributable reserve.

This reserve accounts for movements from the revenue column of the Income statement, the payment of dividends, the buy-back of shares, transfers from the share premium and capital redemption reserve, and other non-capital realised movements.

Dividends
Dividends by the Company are accounted for when the liability to make the payment (record date) has been established.

Segmental reporting
The Directors are of the opinion that the Company is engaged in a single operating segment of business, being investment in smaller early stage companies principally based in the UK.

3. Gains/(losses) on investments

	Year ended 30 June 2024 £'000	Year ended 30 June 2023 £'000
Unrealised gains on fixed asset investments	**3,089**	3,803
Realised losses on fixed asset investments	**(396)**	(178)
Unwinding of discount on deferred consideration	**124**	221
	2,817	3,846

4. Investment income

	Year ended 30 June 2024 £'000	Year ended 30 June 2023 £'000
Loan stock interest	**636**	569
Income from fixed term funds	**357**	145
Bank interest	**351**	138
Dividend income	**114**	84
	1,458	936

5. Investment Manager's fees

	Year ended 30 June 2024			Year ended 30 June 2023		
	Revenue £'000	**Capital £'000**	**Total £'000**	Revenue £'000	Capital £'000	Total £'000
Investment management fee	**160**	**1,438**	**1,598**	153	1,380	1,533
Performance incentive fee	**-**	**-**	**-**	-	-	-
	160	**1,438**	**1,598**	153	1,380	1,533

Further details of the Investment Management Agreement under which the investment manager's fee is paid are given in the Strategic report on page 18.

During the year, services of a total value of £1,648,000 (2023: £1,583,000) were purchased by the Company from Albion Capital Group LLP ("Albion") comprising £1,598,000 of management fees (2023: £1,533,000) and £50,000 of administration fees (2023: £50,000). There is no performance incentive fee payable this year (2023: £nil). At the financial year end, the amount due to Albion in respect of these services disclosed as accruals and deferred income was £435,000 (administration fee accrual: £12,500, management fee accrual £422,500) (2023: £422,500).

Albion is, from time to time, eligible to receive an arrangement fee and monitoring fees from portfolio companies. During the year ended 30 June 2024 fees of £154,000 attributable to the investments of the Company were received pursuant to these arrangements (2023: £299,000).

Albion, its partners and staff holds 2,616,256 Ordinary shares in the Company as at 30 June 2024.

The Company entered into an agreement relating to the Albion VCTs' Prospectus Top Up Offers 2023/24 with the Company's investment manager, Albion, pursuant to which Albion received a fee of 3.0% of the gross proceeds of the Offers and out of which Albion paid the costs of the Offer, as detailed in the Prospectus.

6. Other expenses

	Year ended 30 June 2024 £'000	Year ended 30 June 2023 £'000
Directors' fees (including NIC)	**129**	109
Auditor's remuneration for statutory audit services (excluding VAT)	**53**	48
Secretarial and administration fee	**50**	50
Other administrative expenses	**280**	225
	512	432

7. Directors' fees

The amounts paid to and on behalf of the Directors during the year are as follows:

	Year ended 30 June 2024 £'000	Year ended 30 June 2023 £'000
Directors' fees	**118**	100
National insurance	**11**	9
	129	109

The Company's key management personnel are the Directors. Further information regarding Directors' remuneration can be found in the Directors' remuneration report on pages 62 and 63.

8. Tax (charge)/credit on ordinary activities

	Year ended 30 June 2024 £'000	Year ended 30 June 2023 £'000
UK corporation tax charge	**-**	-

Reconciliation of profit on ordinary activities to taxation charge	**Year ended 30 June 2024 £'000**	Year ended 30 June 2023 £'000
Return on ordinary activities before taxation	**2,165**	2,817
Tax charge on profit at the average rate of 25.0% (2023: 20.5%)	**541**	577
Factors affecting the charge:		
Non-taxable gains	**(704)**	(788)
Income not taxable	**(28)**	(17)
Unutilised management expenses	**191**	228
	-	-

Notes

(i) Venture Capital Trusts are not subject to corporation tax on capital gains.

(ii) Tax relief on expenses charged to capital has been determined by allocating tax relief to expenses by reference to the applicable corporation tax rate and allocating the relief between revenue and capital in accordance with the SORP.

(iii) The Company has excess management expenses of £22,158,000 (2023: £21,392,000) that are available for offset against future profits. A deferred tax asset of £5,540,000 (2023: £5,384,000) has not been recognised in respect of these losses as they will be recoverable only to the extent that the Company has sufficient future taxable profits.

9. Dividends

	Year ended 30 June 2024 £'000	Year ended 30 June 2023 £'000
First dividend of 0.83 pence per share paid on 30 November 2023 (30 November 2022 – 0.84 pence per share)	**2,333**	2,130
Second dividend of 0.78 pence per share paid on 28 March 2024 (31 March 2023 – 0.79 pence per share)	**2,190**	2,120
Unclaimed dividends	**(9)**	(13)
	4,514	4,237

In addition to the dividends paid above, the Board has declared a first dividend for the year ending 30 June 2025 of 0.81 pence per share. This will be paid on 29 November 2024 to shareholders on the register on 8 November 2024. The total dividend will be approximately £2,441,000. All dividends are paid from the other distributable reserve.

During the year, unclaimed dividends older than twelve years of £9,000 (2023: £13,000) were returned to the Company in accordance with the terms of the Articles of Association and have been accounted for on an accruals basis.

10. Basic and diluted return per share

	Year ended 30 June 2024			Year ended 30 June 2023		
	Revenue	**Capital**	**Total**	Revenue	Capital	Total
Return attributable to equity shares (£'000)	**786**	**1,379**	**2,165**	351	2,466	2,817
Weighted average shares in issue (adjusted for treasury shares)	**287,834,982**			266,724,287		
Return attributable per equity share (pence)	**0.27**	**0.48**	**0.75**	0.13	0.92	1.05

The weighted average number of shares is calculated after adjusting for treasury shares of 45,787,992 (2023: 43,285,891).

There are no convertible instruments, derivatives or contingent share agreements in issue so basic and diluted return/(loss) per share are the same.

11. Fixed asset investments

Investments held at fair value through profit or loss	**30 June 2024 £'000**	30 June 2023 £'000
Unquoted equity	**68,025**	57,468
Unquoted loan stock	**9,590**	10,272
Total unquoted investments	**77,615**	67,740
Quoted equity	**64**	260
	77,679	68,000
Opening valuation	**68,000**	57,170
Purchases at cost	**9,832**	7,870
Disposal proceeds	**(2,772)**	(684)
Realised loss	**(396)**	(178)
Movement in loan stock accrued income	**(74)**	19
Unrealised gains	**3,089**	3,803
Closing valuation	**77,679**	68,000
Movement in loan stock accrued income		
Opening accumulated loan stock accrued income	**161**	142
Movement in loan stock accrued income	**(74)**	19
Closing accumulated loan stock accrued income	**87**	161
Movement in unrealised gains		
Opening accumulated unrealised gains	**26,336**	20,317
Transfer of previously unrealised gains to realised reserves on realisations of investments	**746**	2,216
Unrealised gains	**3,089**	3,803
Closing accumulated unrealised gains	**30,171**	26,336
Historic cost basis		
Opening book cost	**41,503**	36,711
Purchases at cost	**9,832**	7,870
Disposals at cost	**(3,915)**	(3,078)
Closing book cost	**47,420**	41,503

Purchases and disposals detailed above may not agree to the Statement of cash flows due to restructuring of investments, conversion of convertible loan stock and settlement receivables and payables.

Loan stock accrued income above, represents only the loan stock interest which has been recognised as revenue on the basis that it is expected to be received in accordance with the accounting policy in note 1. Where loan stock interest does not meet the note 1 recognition criteria for investment income, it forms part of the investment valuation where this is supported by the overall valuation of the portfolio company, and is included within the unrealised gains and losses on investments.

Unquoted fixed asset investments are valued at fair value in accordance with the IPEV guidelines as follows:

Valuation methodology	30 June 2024 £'000	30 June 2023 £'000
Cost and price of recent investment (calibrated and reviewed for impairment)	**45,580**	40,107
Revenue multiple	**16,187**	11,281
Discounted cash flow (supported by third party valuation)	**5,855**	7,358
Earnings multiple (supported by third party valuation)	**4,145**	4,595
Earnings multiple	**2,625**	2,472
Net assets	**891**	971
Discounted offer price	**2,332**	956
	77,615	67,740

When using the cost or price of a recent investment in the valuations, the Company looks to re-calibrate this price at each valuation point by reviewing progress within the investment, comparing against the initial investment thesis, assessing if there are any significant events or milestones that would indicate the value of the investment has changed and considering whether a market-based methodology (i.e. using multiples from comparable public companies) or a discounted cashflow forecast would be more appropriate. The background to the transaction is also considered when the price of investment may not be an appropriate measure of fair value, for example, disproportionate dilution of existing investors from a new investor coming on board or the market conditions at the time of investment no longer being a true reflection of fair value.

The main inputs into the calibration exercise, and for the valuation models using multiples, are revenue, EBITDA and P/E multiples (based on the most recent revenue, EBITDA or earnings achieved for an individual investment and/or equivalent corresponding revenue, EBITDA or earnings multiples of comparable companies), along with quality of earnings assessments and comparability difference adjustments. Revenue multiples are often used, rather than EBITDA or earnings, due to the nature of the Company's investments, being in growth and technology companies which are not normally expected to achieve profitability or scale for a number of years. Where an investment has achieved scale and profitability the Company would normally then expect to switch to using an EBITDA or earnings multiple methodology.

In the calibration exercise and in determining the valuation for the Company's equity instruments, comparable trading multiples are used. In accordance with the Company's policy, appropriate comparable companies based on industry, size, developmental stage, revenue generation and strategy are determined and a trading multiple for each comparable company identified is then calculated. The multiple is calculated by dividing the enterprise value of the comparable group by its revenue, EBITDA or earnings. The trading multiple is then adjusted for considerations such as illiquidity, marketability and other differences, advantages and disadvantages between the portfolio company and the comparable public companies based on company specific facts and circumstances.

As part of the valuation process, the majority of the asset backed businesses also have an annual external third party valuation performed to support the investment managers valuations. The third party valuers are experts in their fields, and have access to many similar business transactions in those speciality areas. Their inclusion forms part of the Manager's fair value assessment.

Fair value investments had the following movements between valuation methodologies between 30 June 2023 and 30 June 2024:

Change in valuation methodology (2023 to 2024)	Value as at 30 June 2024 £'000	Explanatory note
Cost and price of recent investment (calibrated and reviewed for impairment) to revenue multiple	**6,995**	More appropriate valuation methodology
Revenue multiple to discounted offer price	**2,332**	Investment sold shortly after the year end
Revenue multiple to cost and price of recent investment (calibrated and reviewed for impairment)	**817**	Recent funding rounds

The valuation will be the most appropriate valuation methodology for an investment within its market, with regard to the financial health of the investment and the IPEV Guidelines. The Directors believe that, within these parameters, there are no other more relevant methods of valuation which would be reasonable as at 30 June 2024.

FRS 102 and the SORP requires the Company to disclose the inputs to the valuation methods applied to its investments measured at FVTPL in a fair value hierarchy. The table below sets out fair value hierarchy definitions using FRS 102 s.2A.1.

Fair value hierarchy	Definition
Level 1	The unadjusted quoted price in an active market
Level 2	Inputs to valuations are from observable sources and are directly or indirectly derived from prices
Level 3	Inputs to valuations not based on observable market data

The quoted investment is valued according to Level 1 valuation methods (Arecor Therapeutics PLC shown on page 28). Unquoted equity, preference shares and loan stock are all valued according to Level 3 valuation methods.

Investments held at fair value through profit or loss (Level 3) had the following movements:

	30 June 2024 £'000	30 June 2023 £'000
Opening balance	**67,740**	56,410
Purchases at cost*	**9,832**	7,870
Disposal proceeds*	**(2,663)**	(375)
Realised net losses on disposal	**(368)**	(100)
Unrealised gains	**3,148**	3,916
Movement in loan stock accrued income	**(74)**	19
Closing balance	**77,615**	67,740

*Additions and disposals do not agree to the cash flow due to loan stock conversions and non-cash consideration.

The Directors are required to consider the impact of changing one or more of the inputs used as part of the valuation process to reasonable possible alternative assumptions. 77% of the portfolio of investments, consisting of equity and loan stock, is based on recent investment price, discount offer price, net assets and cost and is therefore not sensitised. For the remainder of the portfolio, the Board has considered the reasonable possible alternative input assumptions on the valuation of the portfolio and believes that changes to inputs (by adjusting the earnings and revenue multiples) could lead to a change in the fair value of the portfolio. The Board has reviewed the Manager's adjusted inputs for a number of the largest portfolio companies (by value) which covers 13% of the portfolio as shown in the table below. This has resulted in a total coverage of 90% of all the portfolio of investments. The main inputs considered for each type of valuation is as follows:

Valuation technique	Portfolio company sector	Input	Base case*	Change in input	Change in fair value of investments (£'000)	Change in NAV (pence per share)
Revenue multiple	Healthcare (including digital healthcare)	Revenue multiple	5.4x	+0.5x	465	0.15
				-0.5x	(465)	(0.15)
Discounted cash flow (supported by third party valuation)	Renewable energy	Discount factor	7.3%	-0.5%	126	0.04
				+0.5%	(117)	(0.04)
Earnings multiple (supported by third party valuation	Other (including education)	Earnings multiple	15.9x	+1.6x	382	0.13
				-1.6x	(382)	(0.13)
Earnings multiple	Healthcare (including digital healthcare)	Earnings multiple	8.0x	+0.8x	168	0.06
				-0.8x	(168)	(0.06)

* As detailed in the accounting policies on pages 77 and 78, the base case is based on market comparables, discounted where appropriate for marketability, in accordance with the IPEV guidelines.

The impact of these changes could result in an overall increase in the valuation of the unquoted equity investments by £898,000 (0.9% of net assets) or a decrease in the valuation of unquoted equity investments by £889,000 (0.9% of net assets).

Separately, due to the size of the holding in Quantexa and concentration of the portfolio thereof, whilst being based on recent investment price, a 10% change in this valuation would result in a movement of £1,970,000 (2.0% of net assets).

12. Significant interests

The principal activity of the Company is to select and hold a portfolio of investments in unquoted securities. Although the Company, through the Manager, will, in some cases, be represented on the board of the portfolio company, it will not take a controlling interest or become involved in the management of a portfolio company. The size and structure of the companies with unquoted securities may result in certain holdings in the portfolio representing a participating interest without there being any partnership, joint venture or management consortium agreement.

The Company has no interests of greater than 20% of the nominal value of any class of the allotted shares in the portfolio companies as at 30 June 2024.

13. Trade and other receivables

	30 June 2024 £'000	30 June 2023 £'000
Prepayments	**41**	38
Deferred consideration under one year	**19**	1,646
	60	1,684

The deferred consideration in the prior year predominantly related to the sale of G.Network Communications Limited in December 2020. These proceeds were received in January 2024.

The Directors consider that the carrying amount of receivables is not materially different to their fair value.

14. Creditors: amounts falling due within one year

	30 June 2024 £'000	30 June 2023 £'000
Accruals and deferred income	534	520
Trade payables	40	201
Other creditors: funds held pending legal completion of sale	2,210	-
	2,784	721

Funds held pending legal completion of sale relates to cash received from the sale of Egress Software Technologies which completed on 1 July 2024.

The Directors consider that the carrying amount of payables is not materially different to their fair value.

15. Called-up share capital

Allotted, called up and fully paid	£'000
326,884,706 Ordinary shares of 1 penny each at 30 June 2023	3,269
26,321,332 Ordinary shares of 1 penny each issued during the year	263
6,030,596 Ordinary shares of 1 penny each cancelled during the year	(60)
347,175,442 Ordinary shares of 1 penny each at 30 June 2024	**3,472**
43,285,891 Ordinary shares of 1 penny each held in treasury at 30 June 2023	(433)
2,502,101 Ordinary shares of 1 penny each purchased during the year to be held in treasury	(25)
45,787,992 Ordinary shares of 1 penny each held in treasury at 30 June 2024	**(458)**
Voting rights of 301,387,450 Ordinary shares of 1 penny each at 30 June 2024	**3,014**

The total number of shares held in treasury as at 30 June 2024 of 45,787,992 (2023: 43,285,891) represented 13.2% of the shares in issue as at 30 June 2024.

The Company purchased 6,030,596 Ordinary shares for cancellation (2023: nil) during the year at a total cost of £1,770,000 which is included within the other distributable reserve.

The Company also purchased 2,502,101 Ordinary shares for treasury (2023: 7,462,975) during the year at a total cost of £791,000 (2023: £2,359,000) which is included within the other distributable reserve.

Under the terms of the Dividend Reinvestment Scheme Circular dated 26 February 2009, the following new Ordinary shares of nominal value 1 penny each were allotted during the year:

Allotment date	Number of shares allotted	Aggregate nominal value of shares (£'000)	Issue price (pence per share)	Net invested* (£'000)	Opening market price on allotment (pence per share)
30 November 2023	1,197,148	12	31.64	359	30.10
28 March 2024	1,175,395	12	30.43	337	28.90
	2,372,543			**696**	

* Net invested is calculated as the amount received by the Company after the cost of London Stock Exchange listing fees and registrar fees for administrating the Dividend Reinvestment Scheme.

Under the terms of the Albion VCTs' Prospectus Top Up Offers 2023/24, the following new Ordinary shares of nominal value 1 penny each were issued during the year:

Allotment date	Number of shares allotted	Aggregate nominal value of shares (£'000)	Issue price (pence per share)	Net consideration received* (£'000)	Opening market price on allotment (pence per share)
22 March 2024	4,136,204	41	31.06	1,259	28.90
22 March 2024	870,543	9	31.22	265	28.90
22 March 2024	18,334,011	183	31.38	5,581	28.90
16 April 2024	200,409	2	31.06	61	28.90
16 April 2024	32,030	-	31.22	10	28.90
16 April 2024	375,592	4	31.38	114	28.90
	23,948,789			**7,290**	

* Net consideration received is calculated as the amount received by the Company after Offer costs of up to 3.0% as detailed in the Prospectus.

16. Basic and diluted net asset value per share

	30 June 2024	30 June 2023
Basic and diluted net asset value per share (pence)	**32.20**	33.13

The basic and diluted net asset value per share at the year end is calculated in accordance with the Articles of Association and are based upon total shares in issue (adjusted for treasury shares) of 301,387,450 shares as at 30 June 2024 (2023: 283,598,815).

17. Financial instruments risk management

The Company's financial instruments comprise equity and loan stock investments in quoted and unquoted companies, cash balances and short term receivables and payables which arise from its operations. The main purpose of these financial instruments is to generate cash flow, revenue and capital appreciation for the Company's operations. The Company has no gearing or other financial liabilities apart from short term payables. The Company does not use any derivatives for the management of its Balance sheet.

The principal risks arising from the Company's operations are:

- market risk;
- investment risk (which comprises investment price risk);
- interest rate risk;
- credit risk; and
- liquidity risk.

The Board regularly reviews and agrees policies for managing each of these risks. There have been no changes in the nature of the risks that the Company has faced during the past year and there have been no changes in the objectives, policies or processes for managing risks during the past year. The key risks are summarised below:

Market risk

As a Venture Capital Trust, it is the Company's specific nature to evaluate the market risk of its portfolio of investments in unquoted companies. Market risk is the exposure of the Company to either the revaluation and/or the devaluation of its investments as a result of macroeconomic changes. The main drivers of market risk is the dynamics of market quoted comparators, as well as the financial and operational performance of portfolio companies, as well as the market's appetite for unquoted companies and investor appetite for either trade sales or flotations on public markets. The Board seeks to reduce this risk by having a spread of investments across a variety of sectors. More details on the sectors the Company invests in can be found in the pie chart on page 14.

The Manager and the Board formally review market risk, both at the time of initial investment and at quarterly Board meetings.

The Board monitors the prices at which sales of investments are made to ensure that profits to the Company are maximised, and that valuations of investments retained within the portfolio appear sufficiently prudent and realistic compared to prices being achieved in the market for sales of similar unquoted investments.

Under FRS 102 the Board is required to illustrate by way of a sensitivity analysis the extent to which the assets are exposed to market risk. In order to show the impact of sensitivity in market movements on the Company, a 10% increase or decrease in the valuation of the fixed asset investment portfolio (keeping all other variables constant) would increase or decrease the net asset value and return for the year by £7,768,000. Accordingly, a 20% increase or decrease in the valuation of the fixed asset investment portfolio (keeping all other variables constant) would increase or decrease the net asset value and return for the year by £15,536,000. Further sensitivity analysis on fixed asset investments is included in note 11.

Investment risk (including investment price risk)

Investment risk (including investment price risk) is the risk that the fair value of future investment cash flows will fluctuate due to factors specific to an investment instrument or to a market in similar instruments. The management of risk within the venture capital portfolio is addressed through careful investment selection, by diversification across different industry segments, by maintaining a wide spread of holdings in terms of financing stage and by limitation of the size of individual holdings. The Manager receives management accounts from portfolio companies and members of the investment management team often sit on the boards of unquoted portfolio companies; this enables the close identification, monitoring and management of investment risk. The Directors monitor the Manager's compliance with the investment policy, review and agree policies for managing this risk and monitor the overall level of risk on the investment portfolio on a regular basis.

Valuations are based on the most appropriate valuation methodology for an investment within its market, with regard to the financial health of the investment and follow the IPEV Guidelines. Details of the industries in which investments have been made are contained in the pie chart in the Strategic report on page 14.

The maximum investment risk on the balance sheet date is the value of the fixed asset investment portfolio which is £77,679,000 (2023: £68,000,000). Fixed asset investments form 80% of the net asset value on 30 June 2024 (2023: 72%).

Interest rate risk

Interest rate risk is the possibility of a decline in the value of an asset resulting from unexpected changes in interest rates. It is the Company's policy to accept a degree of interest rate risk on its financial assets through the effect of interest rate changes. On the basis of the Company's analysis, it is estimated that a rise or fall of 1% in all interest rates would have increased or decreased total return before tax for the year by approximately £235,000 (2023: £265,000).

The weighted average interest rate applied to the Company's fixed rate assets during the year was approximately 8.1% (2023: 7.2%). The weighted average period to maturity for the fixed rate assets is approximately 2.0 years (2023: 2.1 years).

The Company's financial assets and liabilities, all denominated in pounds sterling, consist of the following:

	30 June 2024				30 June 2023			
	Fixed rate £'000	**Floating rate £'000**	**Non-interest £'000**	**Total £'000**	Fixed rate £'000	Floating rate £'000	Non-interest £'000	Total £'000
Loan stock	**6,409**	**-**	**3,181**	**9,590**	9,263	-	1,009	10,272
Equity	**-**	**-**	**68,089**	**68,089**	-	-	57,728	57,728
Receivables*	**-**	**-**	**19**	**19**	-	-	1,646	1,646
Payables	**-**	**-**	**(2,784)**	**(2,784)**	-	-	(721)	(721)
Cash	**9,511**	**12,578**	**-**	**22,089**	-	25,006	-	25,006
	15,920	**12,578**	**68,505**	**97,003**	9,263	25,006	59,662	93,931

*The receivables do not reconcile to the Balance sheet as prepayments are not included in the above table.

Credit risk

Credit risk is the risk that the counterparty to a financial instrument will fail to discharge an obligation or commitment that it has entered into with the Company. The Company is exposed to credit risk through its receivables, investment in unquoted loan stock, and through the holding of cash on deposit with banks.

The Manager evaluates credit risk on loan stock and other similar instruments prior to investment, and as part of its ongoing monitoring of investments. In doing this, it takes into account the extent and quality of any security held. For loan stock investments made prior to 6 April 2018, which account for 80.8% of loan stock by value, typically loan stock instruments have a fixed or floating charge, which may or may not have been subordinated, over the assets of the portfolio company in order to mitigate the gross credit risk.

The Manager receives management accounts from portfolio companies, and members of the investment management team often have observer rights or sit on the boards of unquoted portfolio companies; this enables the close identification, monitoring and management of investment-specific credit risk.

The Manager and the Board formally review credit risk (including receivables) and other risks, both at the time of initial investment and at quarterly Board meetings.

The Company's total gross credit risk at 30 June 2024 was limited to £9,590,000 of unquoted loan stock instruments (2023: £10,272,000), £22,089,000 cash deposits with banks (2023: £25,006,000) and £19,000 of other receivables (2023: £1,646,000).

At the balance sheet date, the cash in bank and at hand held by the Company was held with Lloyds Bank Plc, Scottish Widows Bank plc (part of Lloyds Banking Group), Barclays Bank plc, National Westminster Bank plc and Bank of Montreal. Credit risk on cash transactions was mitigated by transacting with counterparties that are regulated entities subject to prudential supervision, with high credit ratings assigned by international credit-rating agencies.

The Company has an informal policy limiting counterparty banking and floating rate note exposure to a maximum of 20% of net asset value for any one counterparty.

The credit profile of unquoted loan stock is described under liquidity risk.

Liquidity risk

Liquidity risk refers to how easily the Company can convert its investments into cash if funds are needed. Liquidity risk is considered one of the principal risks included in the Strategic report on page 25.

Liquid assets are held as cash on current account, on deposit or short term money market account. Under the terms of its Articles, the Company has the ability to borrow up to the amount of its adjusted capital and reserves of the latest published audited Balance sheet, which amounts to £94,603,000 as at 30 June 2024 (2023: £91,615,000).

The Company has no committed borrowing facilities as at 30 June 2024 (2023: nil) and had cash balances of £22,089,000 (2023: £25,006,000). The main cash outflows are for new investments, dividends and share buy-backs, which are within the control of the Company. The Manager formally reviews the cash requirements of the Company on a monthly basis, and the Board on a quarterly basis, as part of its review of management accounts and forecasts. All of the Company's financial liabilities are short term in nature and total £2,784,000 as at 30 June 2024 (2023: £721,000).

The carrying value of loan stock investments as analysed by expected maturity dates is as follows:

	30 June 2024				30 June 2023			
	Fully performing	**Past due**	**Valued below cost**	**Total**	Fully performing	Past due	Valued below cost	Total
Redemption date	**£'000**	**£'000**	**£'000**	**£'000**	£'000	£'000	£'000	£'000
Less than one year	**5,620**	**600**	**609**	**6,829**	6,027	971	-	6,998
1-2 years	**39**	**-**	**-**	**39**	110	-	-	110
2-3 years	**206**	**-**	**-**	**206**	39	-	-	39
3-5 years	**1,525**	**-**	**-**	**1,525**	2,086	-	-	2,086
5 + years	**991**	**-**	**-**	**991**	1,039	-	-	1,039
Total	**8,381**	**600**	**609**	**9,590**	9,301	971	-	10,272

Loan stock can be past due as a result of interest or capital not being paid in accordance with contractual terms. The cost of loan stock investments valued below cost is £657,000 (2023: £nil).

The Company does not hold any assets as the result of the enforcement of security during the period, and believes that the carrying values for both those valued below cost and past due assets are covered by the value of security held for these loan stock investments.

In view of the availability of adequate cash balances and the repayment profile of loan stock investments, the Board considers that the Company is subject to low liquidity risk.

Fair values of financial assets and financial liabilities

All the Company's financial assets and liabilities as at 30 June 2024 are stated at fair value as determined by the Directors, with the exception of receivables, payables and cash which are carried at amortised cost. There are no financial liabilities other than payables. The Company's financial liabilities are all non-interest bearing. It is the Directors' opinion that the book value of the financial liabilities is not materially different to the fair value and all are payable within one year.

18. Commitments and contingencies

The Company had no financial commitments in respect of investments at 30 June 2024 (2023: £nil).

There are no contingencies or guarantees of the Company as at 30 June 2024 (2023: £nil).

19. Post balance sheet events

Since the year end, the Company has completed the following material investment transactions:

- Legal completion of the sale of Egress Software Technologies on 1 July 2024, of which £2,210,000 of funds had been received before 30 June 2024 and were held as a creditor in the Company at 30 June 2024; and
- On 24 July 2024, the Company announced, as part of a joint announcement with the other Albion managed VCTs, that it had entered into discussions regarding possible mergers of the Albion VCTs. Further details of this will be made available in due course.

20. Related party transactions

Other than transactions with the Manager as disclosed in note 5, and the Directors' remuneration disclosed in the Directors' remuneration report on page 62, there are no other related party transactions or balances requiring disclosure.

NOTICE OF ANNUAL GENERAL MEETING

SHAREHOLDERS SHOULD TAKE NOTE THAT THIS WILL BE A VIRTUAL AGM AND FURTHER DETAILS WILL BE MADE AVAILABLE AT WWW.ALBION.CAPITAL/VCT-FUNDS/CRWN.

Notice is hereby given that the Annual General Meeting of Albion Crown VCT PLC (the "Company") will be held virtually at noon on 26 November 2024 for the purposes of considering and, if thought fit, passing the following resolutions, of which resolutions 1 to 9 will be proposed as ordinary resolutions and resolutions 10 to 12 will be proposed as special resolutions.

Ordinary Business

1. To receive and adopt the Company's accounts for the year ended 30 June 2024 together with the Strategic report and the reports of the Directors and Auditor.
2. To approve the Directors' remuneration report for the year ended 30 June 2024.
3. To re-elect James Agnew as a Director of the Company.
4. To re-elect Pam Garside as a Director of the Company.
5. To re-elect Ian Spence as a Director of the Company.
6. To re-elect Tony Ellingham as a Director of the Company.
7. To re-appoint Johnston Carmichael as Auditor of the Company to hold office from the conclusion of the meeting to the conclusion of the next meeting at which the accounts are to be laid.
8. To authorise the Directors to agree the Auditor's remuneration.

Special Business

9. **Authority to allot shares**

   That the Directors be generally and unconditionally authorised in accordance with section 551 of the Companies Act 2006 (the "Act") to allot Ordinary shares in the capital of the Company ("Ordinary shares") up to an aggregate nominal amount of £691,031 (which comprises approximately 20% of the Company's issued Ordinary shares as at the date of this Notice) provided that this authority shall expire 15 months from the date that this resolution is passed, or, if earlier, at the conclusion of the next Annual General Meeting of the Company, but so that the Company may, before such expiry, make an offer or agreement which would or might require shares to be allotted or rights to subscribe for or convert securities into shares to be granted after such expiry and the Directors may allot shares or grant rights to subscribe for or convert securities into shares pursuant to such an offer or agreement as if this authority had not expired.

10. **Authority for the disapplication of pre-emption rights**

    That, subject to the authority and conditional on the passing of resolution number 9, the Directors be empowered, pursuant to section 570 of the Act, to allot equity securities (within the meaning of section 560 of the Act) for cash pursuant to the authority conferred by resolution number 9 and/or sell Ordinary shares held by the Company as treasury shares for cash as if section 561(1) of the Act did not apply to any such allotment or sale.

    Under this power the Directors may impose any limits or restrictions and make any arrangements which they deem necessary or expedient to deal with any treasury shares, fractional entitlements, record dates, legal, regulatory or practical problems in, or laws of, any territory or other matter, arising under the laws of, or the requirements of any recognised regulatory body or any stock exchange in, any territory or any other matter.

This power shall expire 15 months from the date that this resolution is passed or, if earlier, the conclusion of the next Annual General Meeting of the Company, save that the Company may, before such expiry, make an offer or agreement which would or might require equity securities to be allotted after such expiry and the Directors may allot equity securities in pursuance of any such offer or agreement as if this power had not expired.

11. Authority to purchase own shares

That, subject to and in accordance with the Company's Articles of Association, the Company be generally and unconditionally authorised, pursuant to and in accordance with section 701 of the Act, to make market purchases (within the meaning of section 693(4) of the Act) of Ordinary shares, on such terms as the Directors think fit, provided always that:

(a) the maximum aggregate number of Ordinary shares hereby authorised to be purchased is 51,792,748 or, if lower, such number of Ordinary shares as shall equal 14.99% of the issued Ordinary share capital of the Company at the date of the passing of this resolution;

(b) the minimum price which may be paid for an Ordinary share shall be 1 penny;

(c) the maximum price, exclusive of any expenses, which may be paid for a share shall be an amount equal to the higher of (a) 105% of the average of the middle market quotations for the share, as derived from the London Stock Exchange Daily Official List, for the five business days immediately preceding the date on which the share is purchased; and (b) the amount stipulated by Article 5(1) of the Buy-back and Stabilisation Regulation 2003;

(d) the authority hereby conferred shall, unless previously revoked, varied or renewed, expire 15 months from the date that this resolution is passed or, if earlier, at the conclusion of the next Annual General Meeting; and

(e) the Company may enter into a contract or contracts to purchase shares under this authority before the expiry of the authority which will or may be executed wholly or partly after the expiry of the authority, and may make a purchase of shares in pursuance of any such contract or contracts as if the authority conferred hereby had not expired.

12. Notice period for General Meetings

That the notice required for General Meetings of the Company (other than an Annual General Meeting) shall be not less than 14 clear days.

By Order of the Board

Albion Capital Group LLP
Company Secretary
Registered Office
1 Benjamin Street
London, EC1M 5QL

24 October 2024

Albion Crown VCT PLC is registered in England and Wales with number 03495287

Notes

1. Members entitled to participate in, speak and vote at the Annual General Meeting ("AGM") may appoint a proxy or proxies (who need not be a member of the Company) to exercise these rights in their place at the AGM. A member may appoint more than one proxy, provided that each proxy is appointed to exercise the rights attached to different shares. Proxies may only be appointed by:

   - completing and returning the Form of Proxy enclosed with this Notice to Computershare Investor Services PLC, The Pavilions, Bridgwater Road, Bristol BS99 6ZY; or
   - going to www.eproxyappointment.com and following the instructions provided there; or
   - by having an appropriate CREST message transmitted, if you are a user of the CREST system (including CREST personal members).

   Return of the Form of Proxy will not preclude a member from participating in the meeting and voting. A member may not use any electronic address provided in the Notice of this meeting to communicate with the Company for any purposes other than those expressly stated.

   To be effective the Form of Proxy must be completed in accordance with the instructions and received by the Registrars of the Company by noon on 22 November 2024.

   In accordance with good governance practice, the Company is offering shareholders use of an online service, offered by the Company's registrar, Computershare Investor Services, at www.eproxyappointment.com. Shareholders can use this service to vote or appoint a proxy online. The same voting deadline of noon on 22 November 2024 applies as if you were using your Personalised Voting Form to vote or appoint a proxy by post to vote for you. Shareholders who hold their shares electronically may submit their votes through CREST, by submitting the appropriate and authenticated CREST message so as to be received by the Company's registrar not later than two business days before the start of the meeting. Instructions on how to vote through CREST can be found by accessing the following website: www.euroclear.com. Shareholders should not show this information to anyone unless they wish to give proxy instructions on their behalf.

2. Any person to whom this Notice is sent who is a person nominated under section 146 of the Companies Act 2006 ("the Act") to enjoy information rights (a "Nominated Person") may, under an agreement between him or her and the member by whom he or she was nominated, have a right to be appointed (or to have someone else appointed) as a proxy for the AGM. If a Nominated Person has no such proxy appointment right or does not wish to exercise it, he or she may, under any such agreement, have a right to give instructions to the member as to the exercise of voting rights.

   The statement of rights of members in relation to the appointment of proxies in note 1 above does not apply to Nominated Persons. The rights described in that note can only be exercised by members of the Company.

3. To be entitled to participate in and vote at the AGM (and for the purpose of the determination by the Company of the votes they may cast), members must be registered in the register of members of the Company at noon on 22 November 2024 (or, in the event of any adjournment, on the date which is two business days before the time of the adjourned meeting). Changes to the register of members after the relevant deadline shall be disregarded in determining the rights of any person to participate in and vote at the meeting.

4. CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so for this AGM and any adjournment(s) by using the procedures described in the CREST Manual. CREST personal members or other CREST sponsored members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.

   In order for a proxy appointment or instruction made using the CREST service to be valid, the appropriate CREST message (a "CREST Proxy Instruction") must be properly authenticated in accordance with Euroclear UK and Ireland Limited's specifications, and must contain the information required for such instruction, as described in the CREST Manual (available via www.euroclear.com). The message, regardless of whether it constitutes the appointment of a proxy or is an amendment to the instruction given to a previously appointed proxy must, in order to be valid, be transmitted so as to be received by the issuer's agent by noon on 22 November 2024. For this purpose, the time of receipt will be taken to be the time (as determined by the time stamp applied to the message by the CREST Application Host) from which the issuer's agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means.

   CREST members and, where applicable, their CREST sponsors or voting service provider(s) should note that Euroclear UK and Ireland Limited does not make available special procedures in CREST for any particular message. Normal system timings and limitations will, therefore, apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider, to procure that his or her CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service provider(s) are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.

The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.

5. Any corporation which is a member can appoint one or more corporate representatives who may exercise on its behalf all of its powers as a member provided that they do not do so in relation to the same shares.

6. A copy of this Notice, and other information regarding the meeting, as required by section 311A of the Act, is available from www.albion.capital/vct-funds/CRWN under the 'Financials' section.

7. Any member participating in the meeting has the right to ask questions. The Company must cause to be answered any such question relating to the business being dealt with at the meeting but no such answer need be given if (a) to do so would interfere unduly with the preparation for the meeting or involve the disclosure of confidential information, (b) the answer has already been given on a website in the form of an answer to a question, or (c) it is undesirable in the interests of the Company or the good order of the meeting that the question be answered.

Given that the Company has some 10,000 shareholders, to enable the Board and the Manager to respond to questions, and to ensure sufficient time is devoted to managing the assets on behalf of the shareholders, we ask that you submit no more than two questions per shareholder, which should be of a substantive nature and relating to the business being dealt with at the meeting.

8. Copies of contracts of service and letters of appointment between the Directors and the Company, together with the Register of Directors' Interests in the Ordinary shares of the Company, will be available for inspection at the Registered Office of the Company during normal business hours from the date of this Notice until the conclusion of the meeting. In addition, a copy of the Articles of Association will be available for inspection at the Company's registered office from the date of this Notice until the conclusion of the meeting.

9. Under section 527 of the Act members meeting the threshold requirements set out in that section have the right to require the Company to publish on a website a statement setting out any matter relating to: (i) the audit of the Company's accounts (including the Auditor's report and the conduct of the audit) that are to be laid before the AGM: or (ii) any circumstances connected with an Auditor of the Company ceasing to hold office since the previous meeting at which the annual accounts and reports were laid in accordance with section 437 of the Act. The Company may not require the members requesting any such website publication to pay its expenses in complying with section 527 and 528 of the Act. Where the Company is required to place a statement on a website under section 527 of the Act, it must forward the statement to the Company's Auditor not later than the time when it makes the statement available on the website. The business which may be dealt with at the AGM includes any statement that the Company has been required under section 527 of the Act to publish on a website.

10. Members satisfying the thresholds in Section 338 of the Companies Act 2006 may require the Company to give, to members of the Company entitled to receive notice of the AGM, notice of a resolution which those members intend to move (and which may properly be moved) at the AGM. A resolution may properly be moved at the AGM unless (i) it would, if passed, be ineffective (whether by reason of any inconsistency with any enactment of the Company's constitution or otherwise); (ii) it is defamatory of any person; or (iii) it is frivolous or vexatious. The business which may be dealt with at the AGM includes a resolution circulated pursuant to this right. A request made pursuant to this right may be in hard copy or electronic form, must identify the resolution of which notice is to be given, must be authenticated by the person(s) making it and must be received by the Company not later than 6 weeks before the date of the AGM.

11. Members satisfying the thresholds in Section 388A of the Companies Act 2006 may request the Company to include in the business to be dealt with at the AGM any matter (other than a proposed resolution) which may properly be included in the business at the AGM.

A matter may properly be included in the business at the AGM unless (i) it is defamatory of any person or (ii) it is frivolous or vexatious. A request made pursuant to this right may be in hard copy or electronic form, must identify the matter to be included in the business, must be accompanied by a statement setting out the grounds for the request, must be authenticated by the person(s) making it and must be received by the Company not later than 6 weeks before the date of the AGM.

12. As at 23 October 2024 being the latest practicable date prior to the publication of this Notice, the Company's issued share capital consists of 345,515,332 Ordinary shares with a nominal value of 1 penny each. The Company also holds 45,787,992 Ordinary shares in treasury. Therefore, the total voting rights in the Company as at 23 October 2024 are 299,727,340.

Printed by:

perivan.com

RECYCLED
Paper made from recycled material
FSC® C022913
www.fsc.org



AlbionCapital